

4/12/2000  
priority

robinson - 09 / 833111

Page 1

=> d his

(FILE 'HOME' ENTERED AT 12:08:22 ON 09 FEB 2004)  
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 12:08:49 ON 09 FEB 2004  
L1 157992 S ?ALBUMIN?  
L2 1 S L1 AND ?CEREBUS?

FILE 'BIOSIS' ENTERED AT 12:10:20 ON 09 FEB 2004  
L3 0 S L2

FILE 'MEDLINE' ENTERED AT 12:10:31 ON 09 FEB 2004  
L4 0 S L2

FILE 'USPATFULL, USPAT2' ENTERED AT 12:10:35 ON 09 FEB 2004  
L5 73097 S L1  
E ALBUMIN/CT  
L6 4873 S ALBUMIN?/CT  
L7 9 S L5,L6 AND ?CEREBUS?

FILE 'WPIX' ENTERED AT 12:15:16 ON 09 FEB 2004  
L8 9885 S L1/BIX  
L9 0 S L8 AND ?CEREBUS?/BIX  
L10 3 S ?CEREBUS?/BIX

=> fil wpix

FILE 'WPIX' ENTERED AT 12:18:05 ON 09 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE LAST UPDATED: 5 FEB 2004 <20040205/UP>  
MOST RECENT DERWENT UPDATE: 200409 <200409/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> NEW WEEKLY SDI FREQUENCY AVAILABLE --> see NEWS <<<

>>> SLART (Simultaneous Left and Right Truncation) is now  
available in the /ABEX field. An additional search field  
/BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> ADDITIONAL POLYMER INDEXING CODES WILL BE IMPLEMENTED FROM  
DERWENT UPDATE 200403.  
THE TIME RANGE CODE WILL ALSO CHANGE FROM 018 TO 2004.  
SDIS USING THE TIME RANGE CODE WILL NEED TO BE UPDATED.  
FOR FURTHER DETAILS: <http://thomsonderwent.com/chem/polymers/> <<<

=> d all 110 abeq tech abex tot

L10 ANSWER 1 OF 3 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2002-315799 [35] WPIX  
 DNC C2002-092027  
 TI Producing neuronal cell lines based on the degree of neural commitment and growth factor responsiveness, and the potential to produce neural and non-neural progeny.  
 DC B04 D16  
 IN TROPEPE, V; VAN DER KOOT, D  
 PA (TROP-I) TROPEPE V; (VKOO-I) VAN DER KOOT D  
 CYC 97  
 PI WO 2002026941 A2 20020404 (200235)\* EN 84p C12N005-08  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO  
 RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 AU 2001093586 A 20020408 (200252) C12N005-08  
 US 2002164791 A1 20021107 (200275) C12N005-08  
 ADT WO 2002026941 A2 WO 2001-CA1383 20010928; AU 2001093586 A AU 2001-93586  
 20010928; US 2002164791 A1 Provisional US 2000-236394P 20000929, US  
 2001-966768 20010928  
 FDT AU 2001093586 A Based on WO 2002026941  
 PRAI US 2000-236394P 20000929; US 2001-966768 20010928  
 IC ICM C12N005-08  
 ICS A61K048-00; A61P025-28; C12N005-06  
 AB WO 200226941 A UPAB: 20020603  
 NOVELTY - A novel neuronal cell line (III) and a method for producing it based on the degree of neural commitment and growth factor responsiveness in vitro and the potential to produce neural and non-neural progeny in vivo, are new.  
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:  
 (1) a method (I) for differentiating embryonic stem cells to cells with markers characteristic of neural cells comprising:  
 (a) culturing the embryonic stem cells in a serum free media at low cell density selected to minimize embryonic stem (ES) cell aggregation or embryoid body (EB) formation; and  
 (b) allowing the cells to differentiate;  
 (2) a method (II) for producing secondary neural stem cell colonies, comprising:  
 (a) culturing ES cells in low cell density completely defined serum-free media under conditions in which the ES cells differentiate;  
 (b) dissociating and sub-cloning primary neural cell colonies generated from the ES cells; and  
 (c) administering a growth factor to the dissociated cell neural cells;  
 (3) cells (III) expressing 1 or more neural precursor cell markers and/or one or more neural-specific mRNA molecules and which have multilineage potential;  
 (4) a method (IV) of producing a pre-selected cell type derived from (III), comprising culturing the cells under differentiating conditions that promote formation of the cell type;  
 (5) a method (V) for screening for modulators of cellular differentiation, comprising:  
 (a) culturing pluripotent cells in serum-free media under low density conditions in the presence of the potential modulator;  
 (b) allowing for differentiation of the cells; and  
 (c) detecting any differentiation of the cells and cell types generated (if any);  
 (6) a method (VI) for screening for differentiation factors of cellular development, comprising:  
 (a) culturing the cells in serum free media at low cell density in

the presence of the differentiation factor;

(b) allowing the cells to differentiate; and

(c) detecting differentiation of the cells (if any)

(7) a method (VII) of screening for modulators or differentiation factors of neural development;

(8) a method (VIII) for screening for differentiation factors of cellular development, comprising:

(a) culturing (III) in serum free media and in the presence of a differentiation factor; and

(b) detecting any differentiation of the cells; and

(9) a modulator or differentiation factor (IX) detected by (V) - (VIII).

USE - (I) Is used for analyzing the role of genes in the regulation of neural fate specification and/or for obtaining a homogenous uniform neural cell base. (III) Are used as a supply of cells for transplantation, for treatment of neurodegenerative disorders, for the treatment of diseases and conditions resulting from cell loss or function in the neural system and in gene therapy (the cell is modified to express a gene of interest) (claimed). The neural line cells have a number of uses such as tissue engineering, transplantation, gene therapy and drug discovery.

ADVANTAGE - It has been discovered that in low density cell culture assayed, in the absence of serum-derived or feeder cell-derived factors and in the absence of embryoid body formation, embryonic stem cells directly differentiate into neural cells. The transition from ES cell to neural cell can be enhanced by the inhibition of TGF beta -related signaling, in a manner that is consistent with a default model of neural fate specification, but one which is distinct from *Xenopus* default neuralization.

Dwg.0/7

FS CPI

FA AB; DCN

MC CPI: B04-F02; B04-H06; B04-H06G; B04-H09; B11-C08E1; B11-C10; B12-K04E; B14-S03; B14-S03A; D05-H01; D05-H08; D05-H09

TECH UPTX: 20020603

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Methods: In (I) the density is selected to avoid EB formation, and is preferably 0 - 50 cells/microL or more, especially 10 cells/microL. The differentiating ES cells form at least 1 neurosphere. The serum free media further comprises a cytokine (preferably leukemia inhibitory factor (LIF)), a growth factor (preferably a fibroblast growth factor (FGF), especially FGF2) and/or an inhibitor of transforming growth factor (TGF)-beta-related signaling (preferably the protein Noggin or a member of the *Cerebus* family of proteins).

The ES cells differentiate into a primitive, pluripotent neural stem cell. In (II) the growth factor is FGF. A cytokine (LIF or B27) is administered to the dissociated neural cells.

In (IV) The pre-selected cell type is a neural cell and the differentiating conditions comprise culturing the cell in a serum free media comprising FGF2.

In (V) the modulators comprise any culturing conditions that may modulate cellular differentiation.

In method (VIII) the media further comprises FGF2.

Preferred Cells: In (III) the neural precursor marker nestin is expressed. The neural specific mRNA molecule is Emx2 or HoxB1. (III) Is a primitive neural cells line comprising neural markers, is pluripotent and is produced via (I). (III) may be LIF dependent.

Preferred Modulators: (IX) Is used for modulating cellular proliferation.

ABEX UPTX: 20020603

EXAMPLE - No examples given.

L10 ANSWER 2.OF 3 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1999-106054 [09] WPIX

CR 2003-298696 [29]

DNC C1999-031758

TI Human and murine **cerebus**-like proteins - used for treating tissue defects and degenerative nerve conditions.

DC B04 D16

IN DEROBERTIS, E M; FOLLETTIE, M

PA (GEMY) GENETICS INST INC; (REGC) UNIV CALIFORNIA

CYC 83

PI WO 9901553 A1 19990114 (199909)\* EN 50p C12N015-12

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG  
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG  
UZ VN YU ZW

AU 9878140 A 19990125 (199923) C12N015-12

US 5935852 A 19990810 (199938) C12N015-11

EP 1012278 A1 20000628 (200035) EN C12N015-12

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

MX 2000000242 A1 20010601 (200235) A61K038-18

JP 2002511762 W 20020416 (200242) 57p C12N015-09

AU 749031 B 20020620 (200252) C12N015-12

ADT WO 9901553 A1 WO 1998-US11462 19980603; AU 9878140 A AU 1998-78140  
19980603; US 5935852 A US 1997-887997 19970703; EP 1012278 A1 EP  
1998-926263 19980603; WO 1998-US11462 19980603; MX 2000000242 A1 MX  
2000-242 20000105; JP 2002511762 W WO 1998-US11462 19980603, JP  
1999-507147 19980603; AU 749031 B AU 1998-78140 19980603

FDT AU 9878140 A Based on WO 9901553; EP 1012278 A1 Based on WO 9901553; JP  
2002511762 W Based on WO 9901553; AU 749031 B Previous Publ. AU 9878140,  
Based on WO 9901553

PRAI US 1997-887997 19970703

IC ICM A61K038-18; C12N015-09; C12N015-11; C12N015-12

ICS A61K038-00; A61K048-00; A61P001-04; A61P001-16; A61P001-18;  
A61P009-00; A61P011-00; A61P013-12; A61P017-02; A61P019-00;  
A61P019-02; A61P019-10; A61P021-00; A61P025-00; A61P025-16;  
A61P025-28; A61P029-00; A61P043-00; C07H021-04; C07K014-47;  
C07K014-475; C07K016-18; C07K016-22; C12N001-15; C12N001-19;  
C12N001-21; C12N005-10; C12N015-85; C12P021-02

ICA C12P021-08

ICI C12P021-02; C12R001:91

AB WO 9901553 A UPAB: 20030505

A novel isolated DNA sequence comprises a DNA sequence selected from: (a) nucleotides beginning at # 1, 52, 55, 58, 61, 64, 67, 70, 73, 121, 256, 259, 262, 265, 268, 171, or 484 and ending at # 723 or 801 of the 804 bp DNA sequence given in the specification; and (b) sequences which hybridise to (a) under stringent hybridisation conditions and encode a protein which exhibits **cerebus** activity. Also claimed are: (1) an isolated DNA sequence comprising nucleotides encoding amino acids beginning at #1, 18 to 25, 41, 85 to 91 or 152, and ending at #241 or 267 of the 267 amino acid sequence given in the specification; (2) a vector comprising either of the above DNA molecules in operative association with an expression control sequence; (3) an isolated DNA molecule comprising nucleotides 268-801 of the 272 amino acid sequence given in the specification (sic), or naturally occurring allelic sequences of it; (4) a vector comprising the DNA of (4) in operative association with an expression control sequence; (5) an isolated DNA molecule encoding mammalian **cerebus** protein, comprising nucleotides 268-801 of the 804 bp DNA sequence given in the specification; (6) a vector comprising the DNA of (5) in operative association with an expression control sequence; (7) a host cell transformed with the vector of (2), (4) or (6); (8) a purified mammalian **cerebus** protein comprising the 267 amino acid sequence given in the specification; (9) a purified mammalian **cerebus** protein comprising residues 90-267 of the 272 amino acid sequence given in the specification; and (10) antibodies to the **cerebus** protein of (8) or (9).

USE - The host cell of (7) can be used to produce the mammalian **cerebus** proteins (claimed). Compositions containing the protein can be used in the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The mammalian **cerebus** protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

Dwg.0/0

FS CPI

FA AB

MC CPI: B04-E02F; B04-E08; B04-F0100E; B04-G01; B14-E11; B14-F01B; B14-J01; B14-N10; B14-N12; B14-N13; D05-H08; D05-H11; D05-H12A; D05-H12E; D05-H13; D05-H14; D05-H17A6

L10 ANSWER 3 OF 3 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1992-341631 [42] WPIX

DNN N1992-260573 DNC C1992-151867

TI Evaluating neurological pathological conditions - allowing stimulus impulse to act on isolated animal nerve for measurement of action potential before and after wetting with body fluid.

DC B04 S03

IN HEUSSLEIN, R

PA (PALL) PALL CORP

CYC 5

PI EP 508319 A2 19921014 (199242)\* EN 14p G01N033-48

R: DE ES FR GB IT

EP 508319 A3 19930609 (199404) G01N033-48

ADT EP 508319 A2 EP 1992-105785 19920403; EP 508319 A3 EP 1992-105785 19920403

PRAI DE 1991-4111317 19910408

REP 4.Jnl.Ref

IC ICM G01N033-48

AB EP 508319 A UPAB: 19931115

The method involves exposing a nerve to be body fluid and allowing the action potential of the nerve to be measured. The condition is evaluated based on the potential difference before and the after the exposure of the nerve to be fluid. An isolated nerve is used and the body fluid is not intra-neurally injected, but the nerve is wetted by the fluid.

The nerve used is either the nervus ischiadicus of mice or the spinal nerve root of cattle. The body fluid is **cerebuspinal** liquid, allowing an evaluation of Guillian-Barre Syndrome (GBS) or Multiple Sclerosis (MS).

ADVANTAGE - Uses isolated nerve without intra-neural injection of body fluid.

1/7

Dwg.1/7

FS CPI EPI

FA AB

MC CPI: B04-B04H; B11-C08B; B11-C08E; B12-K04A5

EPI: S03-E14H9

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 12:18:14 ON 09 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Feb 2004 VOL 140 ISS 7  
FILE LAST UPDATED: 8 Feb 2004 (20040208/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot 12

L2 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:781079 HCAPLUS  
DN 135:348851  
ED Entered STN: 26 Oct 2001  
TI **Albumin** fusion proteins with therapeutic proteins for improved shelf-life  
IN Rosen, Craig A.; Haseltine, William A.  
PA Human Genome Sciences, Inc, USA  
SO PCT Int. Appl., 606 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM C12N  
CC 63-3 (Pharmaceuticals)  
Section cross-reference(s): 3, 15

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001079444	A2	20011025	WO 2001-US12013	20010412
	WO 2001079444	A3	20020523		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001074809	A5	20011020	AU 2001-74809	20010412
	EP 1278544	A2	20030129	EP 2001-941457	20010412
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2003125247	A1	20030703	US 2001-833041	20010412
	US 2003171267	A1	20030911	US 2001-833117	20010412
	JP 2003530847	T2	20031021	JP 2001-577428	20010412
	US 2003199043	A1	20031023	US 2001-832501	20010412
	US 2003219875	A1	20031127	US 2001-833118	20010412
	US 2004010134	A1	20040115	US 2001-833245	20010412
PRAI	US 2000-229358P	P	20000412		
	US 2000-199384P	P	20000425		
	US 2000-256931P	P	20001221		
	WO 2001-US12013	W	20010412		

*applicant  
hand date*

- AB The present invention encompasses fusion proteins of **albumin** with various therapeutic proteins. Therapeutic proteins may be stabilized to extend the shelf-life, and/or to retain the therapeutic protein's activity for extended periods of time in solution, in vitro and/or in vivo, by genetically or chemical fusing or conjugating the therapeutic protein to **albumin** or a fragment or variant of **albumin**. Use of **albumin** fusion proteins may also reduce the need to formulate the protein solns. with large excesses of carrier proteins to prevent loss of therapeutic proteins due to factors such as binding to the container. Nucleic acid mols. encoding the **albumin** fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin** fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Thus, plasmid vectors are constructed in which DNA encoding the desired therapeutic protein may be inserted for expression of the **albumin** fusion proteins in yeast (pPPC0005) and mammalian cells (pC4:HSA). Yeast-derived signal sequences from *Saccharomyces cerevisiae* invertase SUC2 gene, or the stanniocalcin or native human serum **albumin** signal peptides, are used for secretion in yeast or mammalian systems, resp. Thus, the fusion product of human growth hormone with residues 1-387 of human serum **albumin** retains essentially intact biol. activity after 5 wk of incubation in tissue culture media at 37°, whereas recombinant human growth hormone used as control lost its biol. activity in the first week. Although the potency of the **albumin** fusion proteins is slightly lower than the unfused counterparts in rapid bioassays, their biol. stability results in much higher biol. activity in the longer term in vitro assay or in vivo assays. Addnl., the present invention encompasses pharmaceutical compns. comprising **albumin** fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin** fusion proteins of the invention.
- ST **albumin** fusion therapeutic protein shelflife
- IT Chemokines  
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (1-309; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (11; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (12; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (15; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (17; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (18; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)

- IT Interleukins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(19; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(1; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(21; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(2; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(331D5; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(3; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(4-1BB; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(4; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(5; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(61164; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(6; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(7; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Bone morphogenetic proteins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



- (9; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Platelet-derived growth factors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(AA; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(ACRP-30; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(ADEC (adenoid expressed chemokine); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(AGF; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(APM-1; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Act-2; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Platelet-derived growth factors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(BB; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(BCMA; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Platelet-derived growth factors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Bv-sis; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, 2; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, 3; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, DGWCC; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines

- RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, DVic-1; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, ELC; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, HCC-1; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, IBICK; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, ILINCK; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, SLC (secondary lymphoid chemokine); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-C, STCP-1; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-X-C, 3; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C-X-C; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C10; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Troponins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(C; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CCC3; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CCF18; **albumin** fusion proteins with therapeutic proteins for

- improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CCR2; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT CD antigens  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CD27; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Glycoproteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CD40-L (antigen CD40 ligand); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CTAP-III (connective tissue activating protein III); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Antigens  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CTLA-8; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokine receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CXCR3; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(**Cerebus**; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Chr19Kine; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Platelet-derived growth factors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(D; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Cytokine receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(DR3 (death receptor 3); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(EDAR; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(EDIRF I protein; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic

- use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(EEC (eosinophil expressed chemokine); **albumin** fusion  
proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(ENA-78 (epithelial neutrophil activating protein-78); **albumin**  
fusion proteins with therapeutic proteins for improved shelf-life)
- IT Hemopoietins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(FLT3 ligand; **albumin** fusion proteins with therapeutic  
proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(HCC-1; **albumin** fusion proteins with therapeutic proteins for  
improved shelf-life)
- IT Troponins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(I; **albumin** fusion proteins with therapeutic proteins for  
improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Ll05-7; **albumin** fusion proteins with therapeutic proteins  
for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(LVEC-1 (liver expressed chemokine 1); **albumin** fusion  
proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(LVEC-2 (liver expressed chemokine 2); **albumin** fusion  
proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Lyn-1; **albumin** fusion proteins with therapeutic proteins for  
improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(M110; **albumin** fusion proteins with therapeutic proteins for  
improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(M11A; **albumin** fusion proteins with therapeutic proteins for  
improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MACK (mammary associated chemokine); **albumin** fusion proteins  
with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MCP-3 $\alpha$  and MCP-3 $\beta$ ; **albumin** fusion proteins with  
therapeutic proteins for improved shelf-life)

- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MCP-4; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MCP-4; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MDC (macrophage-derived chemokine); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Monokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MIG (monokine induced by  $\gamma$ -interferon); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MIG- $\beta$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MIRAP; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(MP52; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(NOGO-66; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(NOGO-A; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(NOGO-B; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(NOGO-C; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Antigens  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(OX-40; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

- (PF4; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(PGBC (pituitary expressed chemokine); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokine receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(RANTES; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(SISD; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(SLC (secondary lymphoid tissue chemokine); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Troponins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(T; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(TAC1; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Cytokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(TARC (thymus and activation regulated cytokine); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(TMEC (T cell mixed lymphocyte reaction expressed chemokine); **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Tarc; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Tim-1; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Troy; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(ZCHEMO-8; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)

- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(ZSIG-35; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Drug delivery systems  
Gene therapy  
Molecular cloning  
(**albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT CD30 (antigen)  
CD40 (antigen)  
Cell adhesion molecules  
Cytokines  
Enzymes, biological studies  
Eotaxin  
Erythropoietin receptors  
Fas ligand  
Fusion proteins (chimeric proteins)  
Granulocyte-macrophage colony-stimulating factor receptors  
Growth factors, animal  
Interferons  
Interleukin 1  
Interleukin 1 receptor antagonist  
Interleukin 11  
Interleukin 13  
Interleukin 14  
Interleukin 15  
Interleukin 17  
Interleukin 18  
Interleukin 1 $\alpha$   
Interleukin 1 $\beta$   
Interleukin 3  
Interleukin 4  
Interleukin 4 receptors  
Interleukin 5 receptors  
Interleukin 6  
Interleukin 6 receptors  
Interleukin 8  
Interleukin 8 receptors  
Interleukin 9  
Lymphotoxin  
Monocyte chemoattractant protein-1  
Neutrophil-activating peptide-2  
Platelet-derived growth factors  
RANTES (chemokine)  
Stem cell factor  
Synthetic gene  
Tumor necrosis factor receptors  
Tumor necrosis factors  
Vascular endothelial growth factor receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(**albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin 10  
Interleukin 12  
Interleukin 2  
Interleukin 5  
Interleukin 7  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(**albumin** fusion proteins with therapeutic proteins for improved shelf-life)

- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(b57; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(chemokine-like protein PF4-414; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Growth factors, animal  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(chondromodulins, -like protein; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(collapsins, antibodies for; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(exodus; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Signal peptides  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(for improved secretion in yeast or mammalian cells; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fractalkines; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Agglutinins and Lectins  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(galectin-4; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(gene Patched-2; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Vascular endothelial growth factor receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(gene flt 1; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Vascular endothelial growth factor receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(gene flt 4; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(gene patched; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(glycodelin-A; **albumin** fusion proteins with therapeutic



- proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(granulocyte chemotactic protein-2; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(gro- $\alpha$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(gro- $\beta$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(gro- $\gamma$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(growth-related oncogene- $\alpha$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(growth-related oncogene- $\beta$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(growth-related oncogene- $\gamma$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Cytokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interferon-inducible IP-10; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin 10 receptors; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin 11; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin 12; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin 13; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic

- use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin 15; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin 17; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin 9; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin C; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin-1 accessory; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(interleukin-2 receptor associated p43; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Lymphokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(lymphotactins; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(macrophage inflammatory protein 3 $\alpha$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(macrophage inflammatory protein 3 $\beta$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(macrophage inflammatory protein 3 $\gamma$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Animal cell  
(mammalian, recombinant expression host; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Antitumor agents  
(melanoma; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(monocyte chemoattractant protein 3; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokine receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(monocyte chemoattractant protein-1; **albumin** fusion proteins

- with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(monocyte chemoattractant protein-2; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokine receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(monocyte chemoattractant protein-4; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(neurotactin; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Growth factors, animal  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(osteogenic protein 2; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Tumor necrosis factor receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(p75; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Plasmid vectors  
(pC4:HSA, for mammalian cell expression; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Plasmid vectors  
(pPPC0005, for yeast expression; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Plasmid vectors  
(pScCHSA, for yeast expression; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Plasmid vectors  
(pScNHSA, for yeast expression; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Placental hormones  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(placenta-derived mitogenic factors; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT *Saccharomyces cerevisiae*  
Yeast  
(recombinant expression host; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT **Albumins**, biological studies  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(serum; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Genetic element  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(signal sequence, for improved secretion in yeast or mammalian cells; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Antibodies  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(single chain; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)

- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(stem cell inhibitory factor; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Growth factors, animal  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(stroma-derived growth factor  $\alpha$  and  $\beta$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(therapeutic; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin 1 receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(type 3; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interleukin 1 receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(type II; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Interferons  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
( $\alpha$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokine receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
( $\beta$  chemokine receptor CCR5; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokine receptors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
( $\beta$  chemokine receptor CCR7; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Transforming growth factors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
( $\beta$ 1-; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Transforming growth factors  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
( $\beta$ 2-; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Chemokines  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
( $\beta$ 9; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT Thrombomodulin  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
( $\beta$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT 78990-62-2P, Calpain  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

- (10a and 10b and 10c; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT 50-56-6P, Oxytocin, biological studies 9002-62-4P, Prolactin, biological studies 9002-67-9P, Luteinizing hormone 9002-68-0P, FSH 9002-72-6P, Growth hormone 9004-10-8P, Insulin, biological studies 9014-42-0P, Thrombopoietin 11000-17-2P, Vasopressin 11096-26-7P, Erythropoietin 33507-63-0P, Substance P 67763-96-6P, Insulin-like growth factor 1 83869-56-1P, GM-CSF 106096-92-8P, Acidic fibroblast growth factor 106096-93-9P, Basic fibroblast growth factor 122191-40-6P, ICE proteinase 123584-45-2P, Fibroblast growth factor 4 129653-64-1P, Fibroblast growth factor 5 130939-41-2P, Fibroblast growth factor 6 130939-66-1P, Neurotrophin 3 140208-23-7P, Plasminogen activator inhibitor-1 141760-45-4P, Furin 142243-03-6P, Plasminogen activator inhibitor-2 143011-72-7P, G-CSF 143375-33-1P, Neurotrophin 4 148348-14-5P, Fibroblast growth factor 3 151185-16-9P, Fibroblast growth factor 9 157857-21-1P, Maspin 164003-41-2P, Fibroblast growth factor 8 185915-22-4P, Fibroblast growth factor 13 187888-07-9P, Endostatin 193363-12-1P, Vascular endothelial growth factor D 203874-76-4P, Fibroblast growth factor 12 204719-95-9P, Fibroblast growth factor 16 214210-47-6P, Neuropilin 1 219563-02-7P, Vascular endothelial growth factor E 227018-38-4P, Neuropilin 2 271597-10-5P, Growth/differentiation factor 1 322637-18-3P, Fibroblast growth factor 18 331718-56-0P, Resistin 332350-92-2P, Bone morphogenetic protein receptor kinase 3
- RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (**albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT 144114-21-6, Retropepsin
- RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT 127464-60-2P, Vascular endothelial growth factor
- RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (isoforms; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT 127361-02-8DP, **Albumin** (human blood serum clone HSA-II/HSA-I-A protein moiety reduced), full-length or subfragment fusion products
- RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (nucleotide sequence; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)
- IT 155945-98-5, PN: US5962255 SEQID: 59 unclaimed DNA 156163-00-7 167728-69-0 167728-70-3 167728-71-4 167728-72-5 167728-73-6 167731-70-6 167731-74-0, PN: US5962255 SEQID: 56 unclaimed DNA 167731-75-1, PN: US5962255 SEQID: 57 unclaimed DNA 167731-76-2, PN: US5962255 SEQID: 58 unclaimed DNA 167731-77-3, PN: US5962255 SEQID: 60 unclaimed DNA 167731-78-4, PN: US5962255 SEQID: 61 unclaimed DNA 167731-79-5 167731-80-8 167731-81-9 167732-10-7 167732-11-8, PN: US5962255 SEQID: 551 unclaimed DNA 167732-12-9 167732-13-0 167732-14-1, PN: US5962255 SEQID: 554 unclaimed DNA 167732-15-2, PN: US5962255 SEQID: 555 unclaimed DNA 167732-16-3 167732-17-4 167732-18-5 167732-19-6, PN: US5962255 SEQID: 98 unclaimed DNA 167732-20-9, PN: US5962255 SEQID: 572 unclaimed DNA 167732-21-0 167732-22-1, PN: US5962255 SEQID: 574 unclaimed DNA 195164-37-5 217893-77-1, GenBank A63614 217893-78-2, GenBank A63615 217893-79-3, GenBank A63616 217893-80-6, GenBank A63617 217893-81-7, GenBank A63618 217893-82-8, GenBank A63619 217893-83-9, GenBank A63620 217893-84-0, GenBank A63621 217893-85-1, GenBank A63622 217893-86-2, GenBank A63624 217893-89-5, GenBank A63627 217893-90-8, GenBank A63628 217893-91-9, GenBank A63629 217893-92-0, GenBank A63630 244008-03-5, PN: WO9947540 SEQID: 3 unclaimed DNA 367319-52-6 367319-53-7 367319-54-8

367319-55-9 367319-56-0 367319-57-1 367319-58-2 367319-59-3  
 367319-60-6 367319-61-7 367319-62-8 367319-63-9 367319-64-0  
 367319-65-1 367319-66-2 370965-07-4 370965-08-5

RL: PRP (Properties)

(unclaimed nucleotide sequence; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)

IT 122024-47-9 131748-18-0 244008-06-8, PN: WO9947540 SEQID: 4 unclaimed DNA 244008-07-9, PN: WO9947540 SEQID: 5 unclaimed DNA 244008-08-0, PN: WO9947540 SEQID: 6 unclaimed DNA 244008-09-1, PN: WO9947540 SEQID: 7 unclaimed DNA 244008-12-6, 8: PN: WO0183510 SEQID: 8 unclaimed DNA 244008-13-7, PN: WO9947540 SEQID: 9 unclaimed DNA 367273-46-9 367273-47-0 367273-48-1 371149-71-2

RL: PRP (Properties)

(unclaimed sequence; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)

IT 102510-92-9P, Inhibin A

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

( $\alpha$ - and  $\beta$ -subunits; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)

IT 9061-61-4P, Nerve growth factor

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

( $\beta$ ; **albumin** fusion proteins with therapeutic proteins for improved shelf-life)

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 12:18:30 ON 09 FEB 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:18:30 ON 09 FEB 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs kwic tot 17

L7 ANSWER 1 OF 9 USPATFULL on STN

AN 2004:31195 USPATFULL

TI Modified transferrin fusion proteins

IN Prior, Christopher P., Philadelphia, PA, UNITED STATES

PA BioRexis Pharmaceutical Corporation (U.S. corporation)

PI US 2004023334 A1 20040205

AI US 2002-231494 A1 20020830 (10)

PRAI US 2001-315745P 20010830 (60)

US 2001-334059P 20011130 (60)

DT Utility

FS APPLICATION

LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004

CLMN Number of Claims: 56

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 15780

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . to a heterologous protein capable of extending the serum half-life of the therapeutic protein. For instance, therapeutic proteins

fused to **albumin** and antibody fragments may exhibit extended serum half-life when compared to the therapeutic protein in the unfused state. See U.S. . . .

DETD . . . systems. A number of proteins have been produced using this system, including tetanus toxin fragment, Bordetella pertussis pertactin, human serum **albumin** and lysozyme.

DETD . . . the size of

11 tumors and can therefore be

marker for primary as well as

disease.

#### Cerebus

GeneSeq

W09849296

**Cerebus** is believed to be involved in the BMP activity, in the presence of the BMP Antagonist useful for

Protein Accession

inhibition

of BMP activity

antagonist **Cerebus**, can

be

Osteosarcoma, abnormal bone

W86032

determined using the following

growth.

assays known in the art: Nat Genet.

2001 Jan.;. . .

L7 ANSWER 2 OF 9 USPATFULL on STN

AN 2002:289250 USPATFULL

TI Transgenic mice containing cerberus gene disruptions

IN Leviten, Michael W., Palo Alto, CA, UNITED STATES

Brennan, Thomas J., South San Francisco, CA, UNITED STATES

PI US 2002162131 A1 20021031

AI US 2001-887552 A1 20010621 (9)

PRAI US 2000-213670P 20000621 (60)

US 2001-266046P 20010201 (60)

US 2001-282668P 20010409 (60)

DT Utility

FS APPLICATION

LREP DELTAGEN, INC., 1003 Hamilton Avenue, Menlo Park, CA, 94025

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 2132

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a cerberus gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . invention may be utilized as models for diseases, disorders, or conditions associated with phenotypes relating to a disruption in a **cerebus** gene.

DETD . . . Pharmaceutical compositions may also include various buffers (e.g., Tris, acetate, phosphate), solubilizers (e.g., Tween, Polysorbate), carriers such as human serum **albumin**, preservatives (thimerosal, benzyl alcohol) and anti-oxidants such as ascorbic acid in order to stabilize pharmaceutical activity. The stabilizing agent may. . .

L7 ANSWER 3 OF 9 USPATFULL on STN

AN 2002:280799 USPATFULL

TI Endoderm, cardiac and neural inducing factors-oligonucleotides for  
expressing murine frazzled (Frzb-1) protein  
IN De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES  
Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)  
PI US 2002156249 A1 20021024  
AI US 2001-903170 A1 20010711 (9)  
RLI Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING  
PRAI US 1996-20150P 19960620 (60)  
DT Utility  
FS APPLICATION  
LREP Attention: Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 38th Floor,  
2029 Century Park East, Los Angeles, CA, 90067-3024  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 1196  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel proteins have been designated "cerberus" and "frzb-1,"  
respectively. **Cerebus** is expressed as a secreted peptide  
during embryogenesis of the *Xenopus* embryo, and is expressed  
specifically in the head organizer region. This new molecule has  
endodermal, cardiac, and neural tissue inducing activity, that should  
prove useful in therapeutic, diagnostic, and clinical applications  
requiring regeneration, differentiation, or repair of these and other  
tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt  
family that acts by binding to Wnt growth factors in the extracellular  
space. A third novel protein is therm PAPC which promotes the formation  
of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1,"  
respectively. **Cerebus** is expressed as a secreted peptide  
during embryogenesis of the *Xenopus* embryo, and is expressed  
specifically in the head organizer.  
DETD . . . other organic acids; anti-oxidants including ascorbic acid; low  
molecular weight (less than about 10 residues) polypeptides; proteins,  
such as serum **albumin**, gelatin or immunoglobulins. Other  
components can include glycine, glutamine, asparagine, arginine, or  
lysine; monosaccharides, disaccharides, and other carbohydrates  
including glucose,  
DETD . . . amino acid sequence to a protein which is immunogenic in the  
species to be immunized, e.g., keyhole limpet hemocyanin, serum  
**albumin**, bovine thyroglobulin, or soybean trypsin inhibitor  
using a bifunctional or derivatizing agent, for example,  
maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine).

L7 ANSWER 4 OF 9 USPATFULL on STN

AN 2002:236237 USPATFULL

TI Endoderm, cardiac and neural inducing factors - murine frazzled (FRZB-1)  
protein  
IN De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES  
Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)  
PI US 2002128441 A1 20020912  
AI US 2001-903325 A1 20010711 (9)  
RLI Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING  
PRAI US 1996-20150P 19960620 (60)  
DT Utility  
FS APPLICATION  
LREP Attention: Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 38th Floor,  
2029 Century Park East, Los Angeles, CA, 90067-3024



CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is therm PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer.

DETD . . . other organic acids; anti-oxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum **albumin**, gelatin or immunoglobulins. Other components can include glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, . . .

DETD . . . amino acid sequence to a protein which is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum **albumin**, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine).

L7 ANSWER 5 OF 9 USPTAFULL on STN

AN 2002:236236 USPTAFULL

TI Endoderm, cardiac and neural inducing factors - oligonucleotides for expressing human frazzled (frzb-1) protein

IN De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES  
Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF

PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

PI US 2002128440 A1 20020912

AI US 2001-903323 A1 20010711 (9)

RLI Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING

PRAI US 1996-20150P 19960620 (60)

DT Utility

FS APPLICATION

LREP Attention: Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 2029 Century  
Park East, 38th Floor, Los Angeles, CA, 90067-3024

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 1198

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt

family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is termed PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer. . . .

DETD . . . other organic acids; anti-oxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum **albumin**, gelatin or immunoglobulins. Other components can include glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, . . . .

DETD . . . amino acid sequence to a protein which is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum **albumin**, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine). . . .

L7 ANSWER 6 OF 9 USPTAFULL on STN

AN 2002:236235 USPTAFULL

TI Endoderm, cardiac and neural inducing factors - human frizzled (frzb-1) protein

IN De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES  
Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF

PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)

PI US 2002128439 A1 20020912

AI US 2001-903188 A1 20010711 (9)

RLI Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING

PRAI US 1996-20150P 19960620 (60)

DT Utility

FS APPLICATION

LREP Attention : Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 38th Floor,  
2029 Century Park East, Los Angeles, CA, 90067-3024

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is termed PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer. . . .

DETD . . . other organic acids; anti-oxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum **albumin**, gelatin or immunoglobulins. Other components can include glycine, glutamine, asparagine, arginine, or

lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, . . .

DETD . . . amino acid sequence to a protein which is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum **albumin**, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, . maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine).

L7 ANSWER 7 OF 9 USPATFULL on STN

AN 2002:228450 USPATFULL

TI Endoderm, cardiac and neural inducing factors - oligonucleotides for expressing xenopus frazzled (frzb-1) protein

IN De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES

PA Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)

PI US 2002123613 A1 20020905

AI US 2001-903171 A1 20010711 (9)

RLI Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING

PRAI US 1996-20150P 19960620 (60)

DT Utility

FS APPLICATION

LREP Attention of Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 38th Floor, 2029 Century Park East, Los Angeles, CA, 90067-3024

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 1198

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the Xenopus embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is therm PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the Xenopus embryo, and is expressed specifically in the head organizer. . . .

DETD . . . other organic acids; anti-oxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum **albumin**, gelatin or immunoglobulins. Other components can include glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, . . .

DETD . . . amino acid sequence to a protein which is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum **albumin**, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine).

L7 ANSWER 8 OF 9 USPATFULL on STN

AN 2002:186249 USPATFULL

TI ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS - XENOPUS PARAXIAL PROTOCADHERIN PROTEIN

IN Robertis, Edward M. De, Pacific Palisades, CA, UNITED STATES  
 Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
 PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)  
 PI US 2002099172 A1 20020725  
 AI US 2001-903187 A1 20010711 (9)  
 RLI Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING  
 PRAI US 1996-20150P 19960620 (60)  
 DT Utility  
 FS APPLICATION  
 LREP Attention of Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 38th Floor,  
 2029 Century Park East, Los Angeles, CA, 90067-3024  
 CLMN Number of Claims: 15  
 ECL Exemplary Claim: 1  
 DRWN 18 Drawing Page(s)  
 LN.CNT 1209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is therm PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer.

DETD . . . other organic acids; anti-oxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum **albumin**, gelatin or immunoglobulins. Other components can include glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, . . .

DETD . . . amino acid sequence to a protein which is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum **albumin**, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine).

L7 ANSWER 9 OF 9 USPATFULL on STN  
 AN 2002:186248 USPATFULL  
 TI ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS.- XENOPUS FRAZZLED (FRZB-1) PROTEIN  
 IN De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES  
 Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
 PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)  
 PI US 2002099171 A1 20020725  
 AI US 2001-903180 A1 20010711 (9)  
 RLI Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING  
 PRAI US 1996-20150P 19960620 (60)  
 DT Utility  
 FS APPLICATION  
 LREP Attention of Charles Berman, OPPENHEIMER WOLFF & DONNELLY LLP, 38th  
 Floor, 2029 Century Park East, Los Angeles, CA, 90067-3024  
 CLMN Number of Claims: 15  
 ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 1210

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is termed PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer. . . .

DETD . . . other organic acids; anti-oxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum **albumin**, gelatin or immunoglobulins. Other components can include glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, . . . .

DETD . . . amino acid sequence to a protein which is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum **albumin**, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine). . . .

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	22	FEB 05	German (DE) application and patent publication number format changes
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004

=> file medline, uspatful, dgene, embase, wpids  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 13:52:47 ON 06 FEB 2004

FILE 'USPATFULL' ENTERED AT 13:52:47 ON 06 FEB 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 13:52:47 ON 06 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 13:52:47 ON 06 FEB 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

=> s albumin fusion proteins  
L1 2835 ALBUMIN FUSION PROTEINS

=> s cerebus protein  
L2 1 CEREBUS PROTEIN

=> s l1 and l2  
L3 0 L1 AND L2

=> s (cerebus protein) and albumin  
L4 0 (CEREBUS PROTEIN) AND ALBUMIN

=> s l2 and fusion  
L5 0 L2 AND FUSION

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Human and murine cerebus-like proteins - used for treating tissue defects  
and degenerative nerve conditions.  
AN 1999-106054 [09] WPIDS  
CR 2003-298696 [29]  
AB WO 9901553 A UPAB: 20030505  
A novel isolated DNA sequence comprises a DNA sequence selected from: (a)  
nucleotides beginning at # 1, 52, 55, 58, 61, 64, 67, 70, 73, 121, 256,  
259, 262, 265, 268, 171, or 484 and ending at # 723 or 801 of the 804 bp  
DNA sequence given in the specification; and (b) sequences which hybridise  
to (a) under stringent hybridisation conditions and encode a protein which  
exhibits cerebus activity. Also claimed are: (1) an isolated DNA sequence  
comprising nucleotides encoding amino acids beginning at #1, 18 to 25, 41,  
85 to 91 or 152, and ending at #241 or 267 of the 267 amino acid sequence  
given in the specification; (2) a vector comprising either of the above  
DNA molecules in operative association with an expression control  
sequence; (3) an isolated DNA molecule comprising nucleotides 268-801 of  
the 272 amino acid sequence given in the specification (sic), or naturally  
occurring allelic sequences of it; (4) a vector comprising the DNA of (4)  
in operative association with an expression control sequence; (5) an  
isolated DNA molecule encoding mammalian **cerebus protein**  
, comprising nucleotides 268-801 of the 804 bp DNA sequence given in the  
specification; (6) a vector comprising the DNA of (5) in operative  
association with an expression control sequence; (7) a host cell

transformed with the vector of (2), (4) or (6); (8) a purified mammalian **cerebus protein** comprising the 267 amino acid sequence given in the specification; (9) a purified mammalian **cerebus protein** comprising residues 90-267 of the 272 amino acid sequence given in the specification; and (10) antibodies to the **cerebus protein** of (8) or (9).

USE - The host cell of (7) can be used to produce the mammalian cerebus proteins (claimed). Compositions containing the protein can be used in the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The mammalian **cerebus protein** containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

Dwg.0/0

ACCESSION NUMBER: 1999-106054 [09] WPIDS  
 CROSS REFERENCE: 2003-298696 [29]  
 DOC. NO. CPI: C1999-031758  
 TITLE: Human and murine cerebus-like proteins - used for treating tissue defects and degenerative nerve conditions.  
 DERWENT CLASS: B04 D16  
 INVENTOR(S): DEROBERTIS, E M; FOLLETTIE, M  
 PATENT ASSIGNEE(S): (GEMY) GENETICS INST INC; (REGC) UNIV CALIFORNIA  
 COUNTRY COUNT: 83  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9901553	A1	19990114	(199909)*	EN	50
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW					
AU 9878140	A	19990125	(199923)		
US 5935852	A	19990810	(199938)		
EP 1012278	A1	20000628	(200035)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
MX 2000000242	A1	20010601	(200235)		
JP 2002511762	W	20020416	(200242)		57
AU 749031	B	20020620	(200252)		

#### APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9901553	A1	WO 1998-US11462	19980603
AU 9878140	A	AU 1998-78140	19980603
US 5935852	A	US 1997-887997	19970703
EP 1012278	A1	EP 1998-926263	19980603
		WO 1998-US11462	19980603
MX 2000000242	A1	MX 2000-242	20000105
JP 2002511762	W	WO 1998-US11462	19980603
		JP 1999-507147	19980603
AU 749031	B	AU 1998-78140	19980603

#### FILING DETAILS:



PATENT NO	KIND		PATENT NO
AU 9878140	A	Based on	WO 9901553
EP 1012278	A1	Based on	WO 9901553
JP 2002511762	W	Based on	WO 9901553
AU 749031	B	Previous Publ. Based on	AU 9878140 WO 9901553

PRIORITY APPLN. INFO: US 1997-887997 19970703

=> file biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.32

20.53

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 4 February 2004 (20040204/ED)

FILE RELOADED: 19 October 2003.

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06  
FEB 2004

L1	2835 S ALBUMIN FUSION PROTEINS
L2	1 S CEREBUS PROTEIN
L3	0 S L1 AND L2
L4	0 S (CEREBUS PROTEIN) AND ALBUMIN
L5	0 S L2 AND FUSION

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

=> s l2

	0 CEREBUS
	1361492 PROTEIN
L6	0 CEREBUS PROTEIN (CEREBUS (W) PROTEIN)

=> file medline, uspatful, dgene, embase, wpids, biosis, japio, fsta, jicst  
COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.85

21.38

FILE 'MEDLINE' ENTERED AT 14:00:26 ON 06 FEB 2004

FILE 'USPATFULL' ENTERED AT 14:00:26 ON 06 FEB 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'JAPIO' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'FSTA' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

=> s 12

L7 1 L2

=> d 17 ti abs ibib tot

L7 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine cerebus-like proteins - used for treating tissue defects and degenerative nerve conditions.

AN 1999-106054 [09] WPIDS

CR 2003-298696 [29]

AB WO 9901553 A UPAB: 20030505

A novel isolated DNA sequence comprises a DNA sequence selected from: (a) nucleotides beginning at # 1, 52, 55, 58, 61, 64, 67, 70, 73, 121, 256, 259, 262, 265, 268, 171, or 484 and ending at # 723 or 801 of the 804 bp DNA sequence given in the specification; and (b) sequences which hybridise to (a) under stringent hybridisation conditions and encode a protein which exhibits cerebus activity. Also claimed are: (1) an isolated DNA sequence comprising nucleotides encoding amino acids beginning at #1, 18 to 25, 41, 85 to 91 or 152, and ending at #241 or 267 of the 267 amino acid sequence given in the specification; (2) a vector comprising either of the above DNA molecules in operative association with an expression control sequence; (3) an isolated DNA molecule comprising nucleotides 268-801 of the 272 amino acid sequence given in the specification (sic), or naturally occurring allelic sequences of it; (4) a vector comprising the DNA of (4) in operative association with an expression control sequence; (5) an isolated DNA molecule encoding mammalian **cerebus protein**, comprising nucleotides 268-801 of the 804 bp DNA sequence given in the specification; (6) a vector comprising the DNA of (5) in operative association with an expression control sequence; (7) a host cell transformed with the vector of (2), (4) or (6); (8) a purified mammalian **cerebus protein** comprising the 267 amino acid sequence given in the specification; (9) a purified mammalian **cerebus protein** comprising residues 90-267 of the 272 amino acid sequence given in the specification; and (10) antibodies to the **cerebus protein** of (8) or (9).

USE - The host cell of (7) can be used to produce the mammalian cerebus proteins (claimed). Compositions containing the protein can be used in the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The mammalian **cerebus protein** containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

Dwg.0/0

ACCESSION NUMBER: 1999-106054 [09] WPIDS  
 CROSS REFERENCE: 2003-298696 [29]  
 DOC. NO. CPI: C1999-031758  
 TITLE: Human and murine cerebus-like proteins - used for  
 treating tissue defects and degenerative nerve  
 conditions.  
 DERWENT CLASS: B04 D16  
 INVENTOR(S): DEROBERTIS, E M; FOLLETTIE, M  
 PATENT ASSIGNEE(S): (GEMY) GENETICS INST INC; (REGC) UNIV CALIFORNIA  
 COUNTRY COUNT: 83  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9901553	A1	19990114	(199909)*	EN	50
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE					
GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG					
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG					
UZ VN YU ZW					
AU 9878140	A	19990125	(199923)		
US 5935852	A	19990810	(199938)		
EP 1012278	A1	20000628	(200035)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
MX 2000000242	A1	20010601	(200235)		
JP 2002511762	W	20020416	(200242)		57
AU 749031	B	20020620	(200252)		

#### APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9901553	A1	WO 1998-US11462	19980603
AU 9878140	A	AU 1998-78140	19980603
US 5935852	A	US 1997-887997	19970703
EP 1012278	A1	EP 1998-926263	19980603
		WO 1998-US11462	19980603
MX 2000000242	A1	MX 2000-242	20000105
JP 2002511762	W	WO 1998-US11462	19980603
		JP 1999-507147	19980603
AU 749031	B	AU 1998-78140	19980603

#### FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9878140	A	WO 9901553
EP 1012278	A1	WO 9901553
JP 2002511762	W	WO 9901553
AU 749031	B	AU 9878140
	Based on	WO 9901553

PRIORITY APPLN. INFO: US 1997-887997 19970703

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004

L1 2835 S ALBUMIN FUSION PROTEINS  
 L2 1 S CEREBUS PROTEIN

L3 0 S L1 AND L2  
L4 0 S (CEREBUS PROTEIN) AND ALBUMIN  
L5 0 S L2 AND FUSION

L6 FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004  
0 S L2

L7 FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, JAPIO, FSTA,  
JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004  
1 S L2

=> s TIMP-1 or tissue inhibitor metalloproteinase-1  
5 FILES SEARCHED...

L8 8080 TIMP-1 OR TISSUE INHIBITOR METALLOPROTEINASE-1

=> s l8 and l1  
L9 5 L8 AND L1

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)

LINE COUNT: 25066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic

acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
 TITLE: Albumin fusion proteins  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Page(s)  
 LINE COUNT: 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
 TITLE: Albumin fusion proteins  
 INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
 Sleep, Darrell, West Bridgford, UNITED KINGDOM  
 Prior, Christopher P., Rosemont, PA, UNITED STATES  
 Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
 Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)

US 2000-199384P 20000425 (60)  
 US 2000-229358P 20000412 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 60  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Page(s)  
 LINE COUNT: 14339  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
 Prior, Christopher P., Rosemont, PA, UNITED STATES  
 Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 59  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 20 Drawing Page(s)  
 LINE COUNT: 13208  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion

proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004

L1 2835 S ALBUMIN FUSION PROTEINS  
L2 1 S CEREBUS PROTEIN  
L3 0 S L1 AND L2  
L4 0 S (CEREBUS PROTEIN) AND ALBUMIN  
L5 0 S L2 AND FUSION

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

L6 0 S L2

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, JAPIO, FSTA, JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004

L7 1 S L2  
L8 8080 S TIMP-1 OR TISSUE INHIBITOR METALLOPROTEINASE-1  
L9 5 S L8 AND L1

=> s l8 and fusion

L10 378 L8 AND FUSION

=> s l10 and albumin

L11 221 L10 AND ALBUMIN

=> s l11 and albumin fragment

L12 5 L11 AND ALBUMIN FRAGMENT

=> d l12 ti abs ibib tot

L12 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion

proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 5 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

NUMBER	DATE
--------	------



PRIORITY INFORMATION: US 2000-256931P 20001221 (60)  
 US 2000-199384P 20000425 (60)  
 US 2000-229358P 20000412 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 29  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Page(s)  
 LINE COUNT: 15415  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 5 USPATFULL on STN

TI **Albumin fusion** proteins  
 AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
 TITLE: **Albumin fusion** proteins  
 INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
 Sleep, Darrell, West Bridgford, UNITED KINGDOM  
 Prior, Christopher P., Rosemont, PA, UNITED STATES  
 Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
 Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	14339	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 4 OF 5 USPATFULL on STN

TI **Albumin fusion** proteins  
 AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using

these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 59  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 13208  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 5 USPATFULL on STN

TI **Albumin fusion** proteins  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 15235  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004

L1 2835 S ALBUMIN FUSION PROTEINS  
L2 1 S CEREBUS PROTEIN  
L3 0 S L1 AND L2  
L4 0 S (CEREBUS PROTEIN) AND ALBUMIN  
L5 0 S L2 AND FUSION

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

L6 0 S L2

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, JAPIO, FSTA, JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004

L7 1 S L2  
L8 8080 S TIMP-1 OR TISSUE INHIBITOR METALLOPROTEINASE-1  
L9 5 S L8 AND L1  
L10 378 S L8 AND FUSION  
L11 221 S L10 AND ALBUMIN  
L12 5 S L11 AND ALBUMIN FRAGMENT

=> s l11 and shelf-life

L13 9 L11 AND SHELF-LIFE

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 9 USPATFULL on STN

TI Biospecific contrast agents

AB Methods and apparatuses for detecting a condition of a sample (including cervical cancers and pre-cancers) through reflectance and/or fluorescence imaging. A sample is obtained. One or more metallic nanoparticles and/or one or more quantum dots are obtained. The one or more metallic nanoparticles and/or one or more quantum dots are coupled to one or more biomarkers of the sample that are associated with the condition. A reflectance and/or fluorescence image of the sample is then taken. The image(s) exhibit characteristic optical scattering from the one or more metallic nanoparticles and/or characteristic fluorescence excitation from the one or more quantum dots to signal the presence of the one or more biomarkers. In this way, the condition can be readily screened or diagnosed.

ACCESSION NUMBER: 2004:31276 USPATFULL

TITLE: Biospecific contrast agents

INVENTOR(S): Sokolov, Konstantin, Austin, TX, UNITED STATES  
Korgel, Brian A., Round Rock, TX, UNITED STATES  
Ellington, Andrew D., Austin, TX, UNITED STATES  
Richards-Kortum, Rebecca, Austin, TX, UNITED STATES

NUMBER	KIND	DATE
-----		

PATENT INFORMATION: US 2004023415 A1 20040205  
APPLICATION INFO.: US 2003-382136 A1 20030305 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361924P	20020305 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michael C. Barrett, Esq., FULBRIGHT & JAWORSKI, L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX, 78701	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	3948	

L13 ANSWER 2 OF 9 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	25066	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 9 USPATFULL on STN

TI Nanoporous particle with a retained target

AB Porous nanostructured materials, such as porous nanostructured liquid and liquid crystalline particles or materials, incorporate a target substantially within the material which selectively binds a chemical of interest which can diffusion within the porous nanostructured material and be bound by the target. The porous nanostructured materials can be dispersed as particles in a medium in which said chemical of interest is located with low turbidity. Markers which detect binding of said

chemical of interest can be maintained in the medium separate and apart from the target, and any active compound (e.g., an enzyme) associated therewith by the porous nanostructured material, such that detectable changes in the marker only result when the active compounds diffuse out of the porous nanostructured materials after the chemical of interest binds to the target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330129 USPATFULL  
TITLE: Nanoporous particle with a retained target  
INVENTOR(S): Anderson, David, Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232340	A1	20031218
APPLICATION INFO.:	US 2002-170214	A1	20020613 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190		
NUMBER OF CLAIMS:	119		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	2555		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 9 USPATFULL on STN

TI **Albumin fusion** proteins  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	15415	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 9 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL

TITLE: **Albumin fusion** proteins

INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)

LINE COUNT: 14339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 9 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL

TITLE: **Albumin fusion** proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES

Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	13208	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L13 ANSWER 7 OF 9 USPATFULL on STN

TI **Albumin fusion proteins**  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: **Albumin fusion proteins**  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L13 ANSWER 8 OF 9 USPATFULL on STN

TI Coated particles, methods of making and using  
AB A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least on nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:159130 USPATFULL  
TITLE: Coated particles, methods of making and using  
INVENTOR(S): Anderson, David M., Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003108743	A1	20030612
	US 6638621	B2	20031028
APPLICATION INFO.:	US 2002-170237	A1	20020613 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-297997, filed on 16 Aug 2000, GRANTED, Pat. No. US 6482517		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190		
NUMBER OF CLAIMS:	107		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	5538		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 9 USPATFULL on STN

TI Multifunctional protease inhibitors and their use in treatment of disease  
AB **Fusion** proteins of protease inhibitors are provided, in particular **fusion** proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the **fusion** proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the **fusion** proteins of the invention are also provide, as well as methods of using the **fusion** proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106306 USPATFULL  
TITLE: Multifunctional protease inhibitors and their use in treatment of disease  
INVENTOR(S): Barr, Philip J., Oakland, CA, UNITED STATES  
Gibson, Helen, Oakland, CA, UNITED STATES  
Pemberton, Philip, San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073217	A1	20030417
APPLICATION INFO.:	US 2001-25514	A1	20011218 (10)

NUMBER DATE



PRIORITY INFORMATION: US 2000-256699P 20001218 (60)  
 US 2001-331966P 20011120 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,  
 CA, 94304-1018  
 NUMBER OF CLAIMS: 35  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 6 Drawing Page(s)  
 LINE COUNT: 3252  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004

L1 2835 S ALBUMIN FUSION PROTEINS  
 L2 1 S CEREBUS PROTEIN  
 L3 0 S L1 AND L2  
 L4 0 S (CEREBUS PROTEIN) AND ALBUMIN  
 L5 0 S L2 AND FUSION

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

L6 0 S L2

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, JAPIO, FSTA, JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004

L7 1 S L2  
 L8 8080 S TIMP-1 OR TISSUE INHIBITOR METALLOPROTEINASE-1  
 L9 5 S L8 AND L1  
 L10 378 S L8 AND FUSION  
 L11 221 S L10 AND ALBUMIN  
 L12 5 S L11 AND ALBUMIN FRAGMENT  
 L13 9 S L11 AND SHELF-LIFE

=> s l11 and N-terminus fusion

L14 0 L11 AND N-TERMINUS FUSION

=> s l11 and C-terminus fusion

L15 0 L11 AND C-TERMINUS FUSION

=> d l11 ti abs ibib 1-25

L11 ANSWER 1 OF 221 USPATFULL on STN

TI Biospecific contrast agents

AB Methods and apparatuses for detecting a condition of a sample (including cervical cancers and pre-cancers) through reflectance and/or fluorescence imaging. A sample is obtained. One or more metallic nanoparticles and/or one or more quantum dots are obtained. The one or more metallic nanoparticles and/or one or more quantum dots are coupled to one or more biomarkers of the sample that are associated with the condition. A reflectance and/or fluorescence image of the sample is then taken. The image(s) exhibit characteristic optical scattering from the one or more metallic nanoparticles and/or characteristic fluorescence excitation from the one or more quantum dots to signal the presence of the one or more biomarkers. In this way, the condition can be readily screened or diagnosed.

ACCESSION NUMBER: 2004:31276 USPATFULL  
 TITLE: Biospecific contrast agents

INVENTOR(S): Sokolov, Konstantin, Austin, TX, UNITED STATES  
Korgel, Brian A., Round Rock, TX, UNITED STATES  
Ellington, Andrew D., Austin, TX, UNITED STATES  
Richards-Kortum, Rebecca, Austin, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023415	A1	20040205
APPLICATION INFO.:	US 2003-382136	A1	20030305 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361924P	20020305 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michael C. Barrett, Esq., FULBRIGHT & JAWORSKI, L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX, 78701	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	3948	

L11 ANSWER 2 OF 221 USPATFULL on STN

TI Biochips for characterizing biological processes  
AB This invention includes biochips for analysis of a variety of molecules, cell components and cells. Embodiments of this invention include devices and methods for the parallel and/or nearly parallel processing of biological analytes. Biochips can comprise a substrate, Raman signal-enhancing structures, and receptors selective and/or specific for the analyte(s) to be assayed. Biochips can be read using a Raman reader and can provide for rapid, sensitive, direct assays for physiological and/or pathophysiological conditions of interest.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31155 USPATFULL  
TITLE: Biochips for characterizing biological processes  
INVENTOR(S): Kreimer, David I., Berkeley, CA, UNITED STATES  
Nufert, Thomas H., Walnut Creek, CA, UNITED STATES  
Ginzburg, Lev, Fremont, CA, UNITED STATES  
Yevin, Oleg A., Oakland, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023293	A1	20040205
APPLICATION INFO.:	US 2002-294385	A1	20021114 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-925189, filed on 8 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-815909, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-670453, filed on 26 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156195P	19990927 (60)
	US 2001-336445P	20011114 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sheldon R. Meyer, FLIESLER DUBB MEYER & LOVEJOY LLP, Fourth Floor, Four Embarcadero Center, San Francisco, CA, 94111-4156	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	37 Drawing Page(s)	
LINE COUNT:	3572	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 221 USPATFULL on STN

TI Proteases

AB The invention provides human proteases (PRTS) and polynucleotides which identify and encode PRTS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PRTS.

ACCESSION NUMBER: 2004:31105 USPATFULL

TITLE: Proteases

INVENTOR(S): Henry, Yue, Sunnyvale, CA, UNITED STATES  
Elliott, Vicki S, San Jose, CA, UNITED STATES  
R Gandhi, Ameena, San Francisco, CA, UNITED STATES  
Lal, Preeti G, Santa Clara, CA, UNITED STATES  
Au-Young, Janice, Brisbane, CA, UNITED STATES  
Tribouley, Catherine M, San Francisco, CA, UNITED STATES  
Delegeane, Angelo M, Milpitas, CA, UNITED STATES  
Baughn, Mariah R, San Leandro, CA, UNITED STATES  
Nguyen, Danniel B, San Jose, CA, UNITED STATES  
Lee, Ernestine A, Albany, CA, UNITED STATES  
Hafalia, April J A, Daly City, CA, UNITED STATES  
Khan, Farrah A, Des Plaines, IL, UNITED STATES  
Chawla, Narinder K, Union City, CA, UNITED STATES  
Yao, Monique G, Carmel, IN, UNITED STATES  
Lu, Dyung Aina M, San Jose, CA, UNITED STATES  
Arvizu, Chandra S, San Jose, CA, UNITED STATES  
Tang, Y Tom, San Jose, CA, UNITED STATES  
Walsh, Roderick T, Canterbury, UNITED KINGDOM  
Azimzai, Yalda, Oakland, CA, UNITED STATES  
Lu, Yan, Palo Alto, CA, UNITED STATES  
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES  
Xu, Yuming, Mountain View, CA, UNITED STATES  
Reddy, Roopa, Sunnyvale, CA, UNITED STATES  
Das, Debopriya, Mountain View, CA, UNITED STATES  
Kearney, Liam, San Francisco, CA, UNITED STATES  
Kallick, Deborah A, Galveston, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023243	A1	20040205
APPLICATION INFO.:	US 2003-311035	A1	20030519 (10)
	WO 2001-US19178		20010613
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304		
NUMBER OF CLAIMS:	116		
EXEMPLARY CLAIM:	1		
LINE COUNT:	8891		

L11 ANSWER 4 OF 221 USPATFULL on STN

TI Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease

AB This invention relates to genes identified from human chromosome 20p13-p12, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate

the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31077 USPATFULL  
TITLE: Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease  
INVENTOR(S): Keith, Tim, Bedford, MA, UNITED STATES  
Little, Randall D., Newtonville, MA, UNITED STATES  
Eerdewegh, Paul Van, Weston, MA, UNITED STATES  
Dupuis, Josee, Newton, MA, UNITED STATES  
Del Mastro, Richard G., Norfolk, MA, UNITED STATES  
Simon, Jason, Westfield, NJ, UNITED STATES  
Allen, Kristina, Hopkinton, MA, UNITED STATES  
Pandit, Sunil, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023215	A1	20040205
APPLICATION INFO.:	US 2002-126022	A1	20020419 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-834597, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-548797, filed on 13 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-129391P	19990413 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053	
NUMBER OF CLAIMS:	73	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	157 Drawing Page(s)	
LINE COUNT:	20001	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies  
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:25127 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018969	A1	20040129

APPLICATION INFO.: US 2001-764875 A1 20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)
	US 2000-246532P	20001108 (60)
	US 2000-249216P	20001117 (60)
	US 2000-249210P	20001117 (60)
	US 2000-226681P	20000822 (60)
	US 2000-225759P	20000814 (60)
	US 2000-225213P	20000814 (60)
	US 2000-227182P	20000822 (60)

US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)

US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 38235

L11 ANSWER 6 OF 221 USPATFULL on STN

TI Molecules for diagnostics and therapeutics  
AB The present invention provides purified human polynucleotides for  
diagnostics and therapeutics (dithp). Also encompassed are the  
polypeptides (DITHP) encoded by dithp. The invention also provides for  
the use of dithp, or complements, oligonucleotides, or fragments thereof  
in diagnostic assays. The invention further provides for vectors and  
host cells containing dithp for the expression of DITHP. The invention  
additionally provides for the use of isolated and purified DITHP to  
induce antibodies and to screen libraries of compounds and the use of  
anti-DITHP antibodies in diagnostic assays. Also provided are  
microarrays containing dithp and methods of use.

ACCESSION NUMBER: 2004:18785 USPATFULL  
TITLE: Molecules for diagnostics and therapeutics  
INVENTOR(S): Hodgson, David M., Ann Arbor, MI, UNITED STATES  
Lincoln, Stephen E., Potomac, MD, UNITED STATES  
Russo, Frank D., Sunnyvale, CA, UNITED STATES  
Albany, Peter A., Berkeley, CA, UNITED STATES  
Banville, Steve C., Sunnyvale, CA, UNITED STATES  
Bratcher, Shawn R., Mountain View, CA, UNITED STATES  
Dufour, Gerard E., Castro Valley, CA, UNITED STATES  
Cohen, Howard J., Palo Alto, CA, UNITED STATES  
Rosen, Bruce H., Menlo Park, CA, UNITED STATES  
Chalup, Michael S., Livingston, TX, UNITED STATES  
Jackson, Jennifer L., Santa Cruz, CA, UNITED STATES  
Jones, Anissa L., San Jose, CA, UNITED STATES  
Yu, Jimmy Y., Fremont, CA, UNITED STATES  
Greenawalt, Lila B., San Jose, CA, UNITED STATES  
Panzer, Scott R., Sunnyvale, CA, UNITED STATES  
Roseberry Lincoln, Ann M., Potomac, MD, UNITED STATES  
Wright, Rachel J., Merivale, NEW ZEALAND  
Daniels, Susan E., Mountain View, CA, UNITED STATES  
PATENT ASSIGNEE(S): Incyte Corporation, Palo Alto, CA, UNITED STATES (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014087	A1	20040122
APPLICATION INFO.:	US 2003-378029	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-980285, filed on 30 Nov 2001, PENDING A 371 of International Ser. No. WO 2000-US15404, filed on 31 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147500P	19990805 (60)
	US 1999-147542P	19990805 (60)
	US 1999-147541P	19990805 (60)
	US 1999-147824P	19990805 (60)
	US 1999-147547P	19990805 (60)
	US 1999-147530P	19990805 (60)
	US 1999-147536P	19990805 (60)
	US 1999-147520P	19990805 (60)
	US 1999-147527P	19990805 (60)
	US 1999-147549P	19990805 (60)
	US 1999-147377P	19990804 (60)
	US 1999-147436P	19990804 (60)
	US 1999-137411P	19990603 (60)
	US 1999-137396P	19990603 (60)
	US 1999-137417P	19990603 (60)
	US 1999-137337P	19990603 (60)
	US 1999-137173P	19990602 (60)
	US 1999-137114P	19990602 (60)
	US 1999-137259P	19990602 (60)
	US 1999-137113P	19990602 (60)
	US 1999-137260P	19990602 (60)
	US 1999-137258P	19990602 (60)
	US 1999-137109P	19990602 (60)
	US 1999-137161P	19990601 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	14819	

L11 ANSWER 7 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		



	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)
	US 2000-246532P	20001108 (60)
	US 2000-249216P	20001117 (60)
	US 2000-249210P	20001117 (60)
	US 2000-226681P	20000822 (60)
	US 2000-225759P	20000814 (60)
	US 2000-225213P	20000814 (60)
	US 2000-227182P	20000822 (60)
	US 2000-225214P	20000814 (60)

US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)

US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 26776

L11 ANSWER 8 OF 221 USPATFULL on STN

TI **Albumin fusion** proteins  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 221 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins  
AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens",

and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13598 USPATFULL  
 TITLE: 7 Human ovarian and ovarian cancer associated proteins  
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16023		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 221 USPATFULL on STN

TI Use of bioactive glass compositions to stimulate osteoblast production  
 AB Compositions comprising bioactive glass compositions or extracts thereof which include ions in an appropriate concentration and ratio that they enhance osteoblast production, and methods of preparation and use thereof, are disclosed. The compositions can be included in implantable devices that are capable of inducing tissue formation in autogeneic, allogeneic and xenogeneic implants, for example as coatings and/or matrix materials. Examples of such devices include prosthetic implants, sutures, stents, screws, plates, tubes, and the like. Aqueous extracts of the bioactive glass compositions, which extracts are capable of stimulating osteoblast production, are also disclosed. The compositions can be used, for example, to induce local tissue formation from a progenitor cell in a mammal, for accelerating allograft repair in a mammal, for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site, and for treating tissue degenerative conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13078 USPATFULL  
 TITLE: Use of bioactive glass compositions to stimulate osteoblast production  
 INVENTOR(S): Hench, Larry L, London, UNITED KINGDOM  
 Polak, Julia M, London, UNITED KINGDOM  
 Buttery, Lee D.k., London, UNITED KINGDOM  
 Xynos, Ioannis D, Nafplion, GREECE  
 Maroothernaden, Jason, London, UNITED KINGDOM

NUMBER	KIND	DATE
-----		

PATENT INFORMATION: US 2004009598 A1 20040115  
 APPLICATION INFO.: US 2003-332731 A1 20030707 (10)  
 WO 2001-US21801 20010711  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX  
 1404, ALEXANDRIA, VA, 22313-1404  
 NUMBER OF CLAIMS: 34  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1301  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies  
 AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L11 ANSWER 12 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies  
 AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of

the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:12968 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES  
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)

US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)

US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 32038  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 221 USPATFULL on STN

TI Methods for the treatment of carcinoma

AB The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells, such as renal cell carcinoma. Such gene amplification is expected to be associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, such as renal cell carcinoma, and may act as predictors



of the prognosis of tumor treatment. The present invention is directed to novel methods of diagnosing and treating tumor, such as renal cell carcinoma or Wilms tumor.

ACCESSION NUMBER: 2004:12653 USPATFULL  
TITLE: Methods for the treatment of carcinoma  
INVENTOR(S): Gerritsen, Mary E., San Mateo, CA, UNITED STATES  
Peale, Franklin V., JR., San Carlos, CA, UNITED STATES  
Wu, Thomas D., San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009171	A1	20040115
APPLICATION INFO.:	US 2003-372683	A1	20030221 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-271690, filed on 16 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-344534P	20011018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6662	

L11 ANSWER 14 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed		

on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L11 ANSWER 15 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7343 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)

US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)

US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

24

EXEMPLARY CLAIM:

1

LINE COUNT:

27694

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7341 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)

US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)

US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 28742  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 221 USPATFULL on STN  
TI Functional MRI agents for cancer imaging  
AB The invention relates to novel magnetic resonance imaging contrast  
agents for imaging cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:4285 USPATFULL  
TITLE: Functional MRI agents for cancer imaging  
INVENTOR(S): Meade, Thomas J., Altadena, CA, United States  
Fraser, Scott, La Canada, CA, United States  
Jacobs, Russell, Arcadia, CA, United States  
PATENT ASSIGNEE(S): Research Corporation Technologies, Inc., Tucson, AZ,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673333	B1	20040106
APPLICATION INFO.:	US 2000-715859		20001117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201816P	20000504 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Hartley, Michael G.	
LEGAL REPRESENTATIVE:	Dorsey & Whitney LLP, Silva, Robin M., Kossiak, Renee M.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2422	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 221 USPATFULL on STN

TI 50 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL  
TITLE: 50 human secreted proteins  
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

NUMBER	DATE
--------	------



PRIORITY INFORMATION: US 2001-262066P 20010118 (60)  
 US 1997-57626P 19970905 (60)  
 US 1997-57663P 19970905 (60)  
 US 1997-57669P 19970905 (60)  
 US 1997-58666P 19970912 (60)  
 US 1997-58667P 19970912 (60)  
 US 1997-58973P 19970912 (60)  
 US 1997-58974P 19970912 (60)  
 US 1998-90112P 19980622 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 2 Drawing Page(s)  
 LINE COUNT: 33379  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 221 USPATFULL on STN

TI Novel human gene relating to respiratory diseases, obesity, and  
 inflammatory bowel disease

AB This invention relates to genes identified from human chromosome  
 20p13-p12, which are associated with various diseases, including asthma.  
 The invention also relates to the nucleotide sequences of these genes,  
 isolated nucleic acids comprising these nucleotide sequences, and  
 isolated polypeptides or peptides encoded thereby. The invention further  
 relates to vectors and host cells comprising the disclosed nucleotide  
 sequences, or fragments thereof, as well as antibodies that bind to the  
 encoded polypeptides or peptides. Also related are ligands that modulate  
 the activity of the disclosed genes or gene products. In addition, the  
 invention relates to methods and compositions employing the disclosed  
 nucleic acids, polypeptides or peptides, antibodies, and/or ligands for  
 use in diagnostics and therapeutics for asthma and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2447 USPATFULL

TITLE: Novel human gene relating to respiratory diseases,  
 obesity, and inflammatory bowel disease

INVENTOR(S): Keith, Tim, Bedford, MA, UNITED STATES  
 Little, Randall D., Newtonville, MA, UNITED STATES  
 Eerdewegh, Paul Van, Weston, MA, UNITED STATES  
 Dupuis, Josee, Newton, MA, UNITED STATES  
 Del Mastro, Richard G., Norfolk, MA, UNITED STATES  
 Simon, Jason, Westfield, NJ, UNITED STATES  
 Allen, Kristin, Hopkinton, MA, UNITED STATES  
 Pandit, Sunil, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002470	A1	20040101
APPLICATION INFO.:	US 2002-277216	A1	20021017 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-126022, filed on 19 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-834597, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-548797, filed on 13 Apr 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN & FINNEGAN, L.L.P., 345 PARK AVENUE, NEW YORK, NY, 10154		
NUMBER OF CLAIMS:	45		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 162 Drawing Page(s)  
LINE COUNT: 15810  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 221 USPATFULL on STN

TI Detection and modulation of Slit and roundabout (Robo) mediated angiogenesis and uses thereof

AB This invention is generally in the field of methods for diagnosis, treatment and prevention of various disorders involving the Slit2 mediated angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:335332 USPATFULL

TITLE: Detection and modulation of Slit and roundabout (Robo) mediated angiogenesis and uses thereof

INVENTOR(S): Geng, Jian-Guo, Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236210	A1	20031225
APPLICATION INFO.:	US 2003-386386	A1	20030310 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362485P	20020308 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Peng Chen, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1337	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)

US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)

US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 22457  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 221 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies  
AB The present invention relates to novel proteins. More specifically,  
isolated nucleic acid molecules are provided encoding novel  
polypeptides. Novel polypeptides and antibodies that bind to these  
polypeptides are provided. Also provided are vectors, host cells, and  
recombinant and synthetic methods for producing human polynucleotides  
and/or polypeptides, and antibodies. The invention further relates to  
diagnostic and therapeutic methods useful for diagnosing, treating,  
preventing and/or prognosing disorders related to these novel  
polypeptides. The invention further relates to screening methods for  
identifying agonists and antagonists of polynucleotides and polypeptides  
of the invention. The present invention further relates to methods  
and/or compositions for inhibiting or enhancing the production and  
function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Birse, Charles E., North Potomac, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED  
STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING		

NUMBER	DATE
--------	------

PRIORITY INFORMATION:

US 2000-205515P	20000519 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-216880P	20000707 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-236367P	20000929 (60)
US 2000-239937P	20001013 (60)
US 2000-249210P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-231243P	20000908 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249265P	20001117 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)

US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)

US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)



US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)

US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 20415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 221 USPATFULL on STN  
TI Compositions and methods for systemic inhibition of cartilage  
degradation  
AB Methods and compositions for inhibiting articular cartilage degradation.  
The compositions preferably include multiple chondroprotective agents,  
including at least one agent that promotes cartilage anabolic activity  
and at least one agent that inhibits cartilage catabolism. The  
compositions may also include one or more pain and inflammation

inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334713 USPATFULL  
TITLE: Compositions and methods for systemic inhibition of cartilage degradation  
INVENTOR(S): Demopulos, Gregory A., Mercer Island, WA, UNITED STATES  
Palmer, Pamela Pierce, San Francisco, CA, UNITED STATES  
Herz, Jeffrey M., Mill Creek, WA, UNITED STATES  
PATENT ASSIGNEE(S): Omeros Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235589	A1	20031225
APPLICATION INFO.:	US 2003-356649	A1	20030131 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-31546, filed on 18 Jan 2002, PENDING A 371 of International Ser. No. WO 2000-US19864, filed on 21 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2001-839633, filed on 20 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US24625, filed on 20 Oct 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353552P	20020201 (60)
	US 1999-144904P	19990721 (60)
	US 1998-107256P	19981105 (60)
	US 1998-105026P	19981020 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OMEROS MEDICAL SYSTEMS, INC., 1420 FIFTH AVENUE, SUITE 2675, SEATTLE, WA, 98101	
NUMBER OF CLAIMS:	155	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	6575	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel endocrine related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "endocrine antigens," and the use of such endocrine antigens for detecting disorders of the endocrine system, particularly the presence of cancers of the endocrine system and endocrine cancer metastases. More specifically, isolated endocrine associated nucleic acid molecules are provided encoding novel endocrine associated polypeptides. Novel endocrine polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human endocrine associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the endocrine system, including cancers of the endocrine system, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the

production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330759 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232975	A1	20031218
APPLICATION INFO.:	US 2002-74024	A1	20020214 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764895, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)

US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)

US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 21828  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 221 USPATFULL on STN

TI Proteases  
AB The invention provides human proteases (PRTS) and polynucleotides which identify and encode PRTS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PRTS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330138 USPATFULL  
TITLE: Proteases  
INVENTOR(S): Delegeane, Angelo M., Milpitas, CA, UNITED STATES  
Gandhi, Ameena R., San Francisco, CA, UNITED STATES  
Hafalia, April J. A., Santa Clara, CA, UNITED STATES  
Lu, Dyung Aina M., San Jose, CA, UNITED STATES  
Arvizu, Chandra S., San Jose, CA, UNITED STATES  
Tribouley, Catherine M., San Francisco, CA, UNITED STATES  
Das, Debopriya, Mountain View, CA, UNITED STATES  
Kallick, Deborah A., Portola Valley, CA, UNITED STATES  
Nguyen, Danniell B., San Jose, CA, UNITED STATES  
Lee, Ernestine A., Castro Valley, CA, UNITED STATES  
Khan, Farrah A., Glen View, IL, UNITED STATES  
Yue, Henry, Sunnyvale, CA, UNITED STATES  
Au-Young, Janice, Brisbane, CA, UNITED STATES  
Griffin, Jennifer A., Fremont, CA, UNITED STATES  
Policky, Jennifer L., San Jose, CA, UNITED STATES

Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES  
 Yang, Junming, San Jose, CA, UNITED STATES  
 Thangavelu, Kavitha, Mountain View, CA, UNITED STATES  
 Ding, Li, Creve Coeur, MO, UNITED STATES  
 Kearney, Liam, San Francisco, CA, UNITED STATES  
 Baughn, Mariah R., San Leandro, CA, UNITED STATES  
 Borowsky, Mark L., Redwood City, CA, UNITED STATES  
 Sanjanwala, Madhusudan, Los Altos, CA, UNITED STATES  
 Yao, Monique G., Carmel, IN, UNITED STATES  
 Burford, Neil, Durham, CT, UNITED STATES  
 Chawla, Narinder K., Union City, CA, UNITED STATES  
 Lal, Preeti G., Santa Clara, CA, UNITED STATES  
 Lee, Sally, San Jose, CA, UNITED STATES  
 Todd, Stephen, San Francisco, CA, UNITED STATES  
 Lo, Terence P., Foster City, CA, UNITED STATES  
 Tang, Y. Tom, San Jose, CA, UNITED STATES  
 Elliott, Vicki S., San Jose, CA, UNITED STATES  
 Azimzai, Yalda, Oakland, CA, UNITED STATES  
 Lu, Yan, Palo Alto, CA, UNITED STATES  
 Incyte Genomics, Inc., Palo Alto, CA (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232349	A1	20031218
APPLICATION INFO.:	US 2002-274639	A1	20021018 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-US22397, filed on 17 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220063P	20000721 (60)
	US 2000-221680P	20000728 (60)
	US 2000-223544P	20000804 (60)
	US 2000-224717P	20000811 (60)
	US 2000-225988P	20000816 (60)
	US 2000-227568P	20000823 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8959	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPplus records now contain indexing from 1907 to the  
present  
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded  
NEWS 5 SEP 29 DISSABS now available on STN  
NEWS 6 OCT 10 PCTFULL: Two new display fields added  
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
NEWS 9 NOV 24 MSDS-CCOHS file reloaded  
NEWS 10 DEC 08 CABA reloaded with left truncation  
NEWS 11 DEC 08 IMS file names changed  
NEWS 12 DEC 09 Experimental property data collected by CAS now available  
in REGISTRY  
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPplus  
NEWS 14 DEC 17 DGENE: Two new display fields added  
NEWS 15 DEC 18 BIOTECHNO no longer updated  
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer  
available  
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS  
databases  
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields  
NEWS 19 DEC 22 ABI-INFORM now available on STN  
NEWS 20 JAN 27 Source of Registration (SR) information in REGISTRY updated  
and searchable  
NEWS 21 JAN 27 A new search aid, the Company Name Thesaurus, available in  
CA/CAPplus  
NEWS 22 FEB 05 German (DE) application and patent publication number format  
changes  
  
NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.



\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004

=> file medline, uspatful, dgene, embase, wpids  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 13:52:47 ON 06 FEB 2004

FILE 'USPATFULL' ENTERED AT 13:52:47 ON 06 FEB 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 13:52:47 ON 06 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 13:52:47 ON 06 FEB 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

=> s albumin fusion proteins  
L1 2835 ALBUMIN FUSION PROTEINS

=> s cerebus protein  
L2 1 CEREBUS PROTEIN

=> s l1 and l2  
L3 0 L1 AND L2

=> s (cerebus protein) and albumin  
L4 0 (CEREBUS PROTEIN) AND ALBUMIN

=> s l2 and fusion  
L5 0 L2 AND FUSION

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Human and murine cerebus-like proteins - used for treating tissue defects  
and degenerative nerve conditions.  
AN 1999-106054 [09] WPIDS  
CR 2003-298696 [29]  
AB WO 9901553 A UPAB: 20030505  
A novel isolated DNA sequence comprises a DNA sequence selected from: (a)  
nucleotides beginning at # 1, 52, 55, 58, 61, 64, 67, 70, 73, 121, 256,  
259, 262, 265, 268, 171, or 484 and ending at # 723 or 801 of the 804 bp  
DNA sequence given in the specification; and (b) sequences which hybridise  
to (a) under stringent hybridisation conditions and encode a protein which  
exhibits cerebus activity. Also claimed are: (1) an isolated DNA sequence  
comprising nucleotides encoding amino acids beginning at #1, 18 to 25, 41,  
85 to 91 or 152, and ending at #241 or 267 of the 267 amino acid sequence  
given in the specification; (2) a vector comprising either of the above  
DNA molecules in operative association with an expression control  
sequence; (3) an isolated DNA molecule comprising nucleotides 268-801 of  
the 272 amino acid sequence given in the specification (sic), or naturally  
occurring allelic sequences of it; (4) a vector comprising the DNA of (4)  
in operative association with an expression control sequence; (5) an  
isolated DNA molecule encoding mammalian **cerebus protein**  
, comprising nucleotides 268-801 of the 804 bp DNA sequence given in the  
specification; (6) a vector comprising the DNA of (5) in operative  
association with an expression control sequence; (7) a host cell

transformed with the vector of (2), (4) or (6); (8) a purified mammalian **cerebus protein** comprising the 267 amino acid sequence given in the specification; (9) a purified mammalian **cerebus protein** comprising residues 90-267 of the 272 amino acid sequence given in the specification; and (10) antibodies to the **cerebus protein** of (8) or (9).

USE - The host cell of (7) can be used to produce the mammalian cerebus proteins (claimed). Compositions containing the protein can be used in the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The mammalian **cerebus protein** containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

Dwg.0/0

ACCESSION NUMBER: 1999-106054 [09] WPIDS  
 CROSS REFERENCE: 2003-298696 [29]  
 DOC. NO. CPI: C1999-031758  
 TITLE: Human and murine cerebus-like proteins - used for treating tissue defects and degenerative nerve conditions.  
 DERWENT CLASS: B04 D16  
 INVENTOR(S): DEROBERTIS, E M; FOLLETTIE, M  
 PATENT ASSIGNEE(S): (GEMY) GENETICS INST INC; (REGC) UNIV CALIFORNIA  
 COUNTRY COUNT: 83  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9901553	A1	19990114	(199909)*	EN	50
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW					
AU 9878140	A	19990125	(199923)		
US 5935852	A	19990810	(199938)		
EP 1012278	A1	20000628	(200035)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
MX 2000000242	A1	20010601	(200235)		
JP 2002511762	W	20020416	(200242)		57
AU 749031	B	20020620	(200252)		

# APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9901553	A1	WO 1998-US11462	19980603
AU 9878140	A	AU 1998-78140	19980603
US 5935852	A	US 1997-887997	19970703
EP 1012278	A1	EP 1998-926263	19980603
		WO 1998-US11462	19980603
MX 2000000242	A1	MX 2000-242	20000105
JP 2002511762	W	WO 1998-US11462	19980603
		JP 1999-507147	19980603
AU 749031	B	AU 1998-78140	19980603

# FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9878140	A	Based on	WO 9901553
EP 1012278	A1	Based on	WO 9901553
JP 2002511762	W	Based on	WO 9901553
AU 749031	B	Previous Publ.	AU 9878140
		Based on	WO 9901553

PRIORITY APPLN. INFO: US 1997-887997 19970703

=> file biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.32

20.53

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 4 February 2004 (20040204/ED)

FILE RELOADED: 19 October 2003.

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06  
FEB 2004

L1	2835	S	ALBUMIN FUSION PROTEINS
L2	1	S	CEREBUS PROTEIN
L3	0	S	L1 AND L2
L4	0	S	(CEREBUS PROTEIN) AND ALBUMIN
L5	0	S	L2 AND FUSION

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

=> s l2

	0	CEREBUS
	1361492	PROTEIN
L6	0	CEREBUS PROTEIN
		(CEREBUS (W) PROTEIN)

=> file medline, uspatful, dgene, embase, wpids, biosis, japio, fsta, jicst

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.85

21.38

FILE 'MEDLINE' ENTERED AT 14:00:26 ON 06 FEB 2004

FILE 'USPATFULL' ENTERED AT 14:00:26 ON 06 FEB 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:00:26 ON 06 FEB 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 14:00:26 ON 06 FEB 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'JAPIO' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'FSTA' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

=> s l2

L7 1 L2

=> d l7 ti abs ibib tot

L7 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine cerebus-like proteins - used for treating tissue defects and degenerative nerve conditions.

AN 1999-106054 [09] WPIDS

CR 2003-298696 [29]

AB WO 9901553 A UPAB: 20030505

A novel isolated DNA sequence comprises a DNA sequence selected from: (a) nucleotides beginning at # 1, 52, 55, 58, 61, 64, 67, 70, 73, 121, 256, 259, 262, 265, 268, 171, or 484 and ending at # 723 or 801 of the 804 bp DNA sequence given in the specification; and (b) sequences which hybridise to (a) under stringent hybridisation conditions and encode a protein which exhibits cerebus activity. Also claimed are: (1) an isolated DNA sequence comprising nucleotides encoding amino acids beginning at #1, 18 to 25, 41, 85 to 91 or 152, and ending at #241 or 267 of the 267 amino acid sequence given in the specification; (2) a vector comprising either of the above DNA molecules in operative association with an expression control sequence; (3) an isolated DNA molecule comprising nucleotides 268-801 of the 272 amino acid sequence given in the specification (sic), or naturally occurring allelic sequences of it; (4) a vector comprising the DNA of (4) in operative association with an expression control sequence; (5) an isolated DNA molecule encoding mammalian **cerebus protein**, comprising nucleotides 268-801 of the 804 bp DNA sequence given in the specification; (6) a vector comprising the DNA of (5) in operative association with an expression control sequence; (7) a host cell transformed with the vector of (2), (4) or (6); (8) a purified mammalian **cerebus protein** comprising the 267 amino acid sequence given in the specification; (9) a purified mammalian **cerebus protein** comprising residues 90-267 of the 272 amino acid sequence given in the specification; and (10) antibodies to the **cerebus protein** of (8) or (9).

USE - The host cell of (7) can be used to produce the mammalian cerebus proteins (claimed). Compositions containing the protein can be used in the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The mammalian **cerebus protein** containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

Dwg.0/0

ACCESSION NUMBER: 1999-106054 [09] WPIDS  
 CROSS REFERENCE: 2003-298696 [29]  
 DOC. NO. CPI: C1999-031758  
 TITLE: Human and murine cerebus-like proteins - used for  
 treating tissue defects and degenerative nerve  
 conditions.  
 DERWENT CLASS: B04 D16  
 INVENTOR(S): DEROBERTIS, E M; FOLLETTIE, M  
 PATENT ASSIGNEE(S): (GEMY) GENETICS INST INC; (REGC) UNIV CALIFORNIA  
 COUNTRY COUNT: 83  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9901553	A1	19990114	(199909)*	EN	50
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE					
GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG					
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG					
UZ VN YU ZW					
AU 9878140	A	19990125	(199923)		
US 5935852	A	19990810	(199938)		
EP 1012278	A1	20000628	(200035)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
MX 2000000242	A1	20010601	(200235)		
JP 2002511762	W	20020416	(200242)		57
AU 749031	B	20020620	(200252)		

#### APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9901553	A1	WO 1998-US11462	19980603
AU 9878140	A	AU 1998-78140	19980603
US 5935852	A	US 1997-887997	19970703
EP 1012278	A1	EP 1998-926263	19980603
		WO 1998-US11462	19980603
MX 2000000242	A1	MX 2000-242	20000105
JP 2002511762	W	WO 1998-US11462	19980603
		JP 1999-507147	19980603
AU 749031	B	AU 1998-78140	19980603

#### FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9878140	A Based on	WO 9901553
EP 1012278	A1 Based on	WO 9901553
JP 2002511762	W Based on	WO 9901553
AU 749031	B Previous Publ.	AU 9878140
	Based on	WO 9901553

PRIORITY APPLN. INFO: US 1997-887997 19970703

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004

L1 2835 S ALBUMIN FUSION PROTEINS  
 L2 1 S CEREBUS PROTEIN

L3 0 S L1 AND L2  
L4 0 S (CEREBUS PROTEIN) AND ALBUMIN  
L5 0 S L2 AND FUSION

L6 FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004  
0 S L2

L7 FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, JAPIO, FSTA,  
JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004  
1 S L2

=> s TIMP-1 or tissue inhibitor metalloproteinase-1  
5 FILES SEARCHED...

L8 8080 TIMP-1 OR TISSUE INHIBITOR METALLOPROTEINASE-1

=> s l8 and l1  
L9 5 L8 AND L1

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s).

LINE COUNT: 25066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic

acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
 TITLE: Albumin fusion proteins  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Page(s)  
 LINE COUNT: 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
 TITLE: Albumin fusion proteins  
 INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
 Sleep, Darrell, West Bridgford, UNITED KINGDOM  
 Prior, Christopher P., Rosemont, PA, UNITED STATES  
 Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
 Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)

US 2000-199384P 20000425 (60)  
 US 2000-229358P 20000412 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 60  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Page(s)  
 LINE COUNT: 14339  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
 Prior, Christopher P., Rosemont, PA, UNITED STATES  
 Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 59  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 20 Drawing Page(s)  
 LINE COUNT: 13208  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion



proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004

L1 2835 S ALBUMIN FUSION PROTEINS  
L2 1 S CEREBUS PROTEIN  
L3 0 S L1 AND L2  
L4 0 S (CEREBUS PROTEIN) AND ALBUMIN  
L5 0 S L2 AND FUSION

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

L6 0 S L2

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, JAPIO, FSTA, JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004

L7 1 S L2  
L8 8080 S TIMP-1 OR TISSUE INHIBITOR METALLOPROTEINASE-1  
L9 5 S L8 AND L1

=> s l8 and fusion

L10 378 L8 AND FUSION

=> s l10 and albumin

L11 221 L10 AND ALBUMIN

=> s l11 and albumin fragment

L12 5 L11 AND ALBUMIN FRAGMENT

=> d l12 ti abs ibib tot

L12 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion

proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 5 USPATFULL on STN

TI **Albumin fusion** proteins  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2000-256931P 20001221 (60)  
 US 2000-199384P 20000425 (60)  
 US 2000-229358P 20000412 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 29  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Page(s)  
 LINE COUNT: 15415  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 5 USPATFULL on STN

TI **Albumin fusion** proteins  
 AB The present invention encompasses **albumin fusion**  
 proteins. Nucleic acid molecules encoding the **albumin**  
**fusion** proteins of the invention are also encompassed by the  
 invention, as are vectors containing these nucleic acids, host cells  
 transformed with these nucleic acids vectors, and methods of making the  
**albumin fusion** proteins of the invention and using  
 these nucleic acids, vectors, and/or host cells. Additionally the  
 present invention encompasses pharmaceutical compositions comprising  
**albumin fusion** proteins and methods of treating,  
 preventing, or ameliorating diseases, disorders or conditions using  
**albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
 TITLE: **Albumin fusion** proteins  
 INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
 Sleep, Darrell, West Bridgford, UNITED KINGDOM  
 Prior, Christopher P., Rosemont, PA, UNITED STATES  
 Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
 Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 60  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Page(s)  
 LINE COUNT: 14339  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 5 USPATFULL on STN

TI **Albumin fusion** proteins  
 AB The present invention encompasses **albumin fusion**  
 proteins. Nucleic acid molecules encoding the **albumin**  
**fusion** proteins of the invention are also encompassed by the  
 invention, as are vectors containing these nucleic acids, host cells  
 transformed with these nucleic acids vectors, and methods of making the  
**albumin fusion** proteins of the invention and using

these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 59  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 13208

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 5 USPATFULL on STN

TI **Albumin fusion** proteins  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 15235  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06 FEB 2004

L1 2835 S ALBUMIN FUSION PROTEINS  
L2 1 S CEREBUS PROTEIN  
L3 0 S L1 AND L2  
L4 0 S (CEREBUS PROTEIN) AND ALBUMIN  
L5 0 S L2 AND FUSION

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

L6 0 S L2

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, JAPIO, FSTA, JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004

L7 1 S L2  
L8 8080 S TIMP-1 OR TISSUE INHIBITOR METALLOPROTEINASE-1  
L9 5 S L8 AND L1  
L10 378 S L8 AND FUSION  
L11 221 S L10 AND ALBUMIN  
L12 5 S L11 AND ALBUMIN FRAGMENT

=> s l11 and shelf-life

L13 9 L11 AND SHELF-LIFE

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 9 USPATFULL on STN

TI Biospecific contrast agents

AB Methods and apparatuses for detecting a condition of a sample (including cervical cancers and pre-cancers) through reflectance and/or fluorescence imaging. A sample is obtained. One or more metallic nanoparticles and/or one or more quantum dots are obtained. The one or more metallic nanoparticles and/or one or more quantum dots are coupled to one or more biomarkers of the sample that are associated with the condition. A reflectance and/or fluorescence image of the sample is then taken. The image(s) exhibit characteristic optical scattering from the one or more metallic nanoparticles and/or characteristic fluorescence excitation from the one or more quantum dots to signal the presence of the one or more biomarkers. In this way, the condition can be readily screened or diagnosed.

ACCESSION NUMBER: 2004:31276 USPATFULL  
TITLE: Biospecific contrast agents  
INVENTOR(S): Sokolov, Konstantin, Austin, TX, UNITED STATES  
Korgel, Brian A., Round Rock, TX, UNITED STATES  
Ellington, Andrew D., Austin, TX, UNITED STATES  
Richards-Kortum, Rebecca, Austin, TX, UNITED STATES

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2004023415 A1 20040205  
APPLICATION INFO.: US 2003-382136 A1 20030305 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361924P	20020305 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michael C. Barrett, Esq., FULBRIGHT & JAWORSKI, L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX, 78701	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	3948	

L13 ANSWER 2 OF 9 USPATFULL on STN

TI **Albumin fusion proteins**  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: **Albumin fusion proteins**  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	25066	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 9 USPATFULL on STN

TI Nanoporous particle with a retained target  
AB Porous nanostructured materials, such as porous nanostructured liquid and liquid crystalline particles or materials, incorporate a target substantially within the material which selectively binds a chemical of interest which can diffusion within the porous nanostructured material and be bound by the target. The porous nanostructured materials can be dispersed as particles in a medium in which said chemical of interest is located with low turbidity. Markers which detect binding of said

chemical of interest can be maintained in the medium separate and apart from the target, and any active compound (e.g., an enzyme) associated therewith by the porous nanostructured material, such that detectable changes in the marker only result when the active compounds diffuse out of the porous nanostructured materials after the chemical of interest binds to the target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330129 USPATFULL  
TITLE: Nanoporous particle with a retained target  
INVENTOR(S): Anderson, David, Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232340	A1	20031218
APPLICATION INFO.:	US 2002-170214	A1	20020613 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190		
NUMBER OF CLAIMS:	119		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	2555		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 9 USPATFULL on STN

TI **Albumin fusion** proteins  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	15415	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 9 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL

TITLE: **Albumin fusion** proteins

INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)

LINE COUNT: 14339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 9 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL

TITLE: **Albumin fusion** proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES



Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	13208	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L13 ANSWER 7 OF 9 USPATFULL on STN

TI **Albumin fusion** proteins  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L13 ANSWER 8 OF 9 USPATFULL on STN

TI Coated particles, methods of making and using  
AB A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least one nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:159130 USPATFULL  
TITLE: Coated particles, methods of making and using  
INVENTOR(S): Anderson, David M., Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003108743	A1	20030612
	US 6638621	B2	20031028
APPLICATION INFO.:	US 2002-170237	A1	20020613 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-297997, filed on 16 Aug 2000, GRANTED, Pat. No. US 6482517		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190		
NUMBER OF CLAIMS:	107		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	5538		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 9 USPATFULL on STN

TI Multifunctional protease inhibitors and their use in treatment of disease

AB **Fusion** proteins of protease inhibitors are provided, in particular **fusion** proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the **fusion** proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the **fusion** proteins of the invention are also provide, as well as methods of using the **fusion** proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106306 USPATFULL  
TITLE: Multifunctional protease inhibitors and their use in treatment of disease  
INVENTOR(S): Barr, Philip J., Oakland, CA, UNITED STATES  
Gibson, Helen, Oakland, CA, UNITED STATES  
Pemberton, Philip, San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073217	A1	20030417
APPLICATION INFO.:	US 2001-25514	A1	20011218 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2000-256699P 20001218 (60)  
US 2001-331966P 20011120 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,  
CA, 94304-1018  
NUMBER OF CLAIMS: 35  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Page(s)  
LINE COUNT: 3252  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:52:01 ON 06 FEB 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 13:52:47 ON 06  
FEB 2004

L1 2835 S ALBUMIN FUSION PROTEINS  
L2 1 S CEREBUS PROTEIN  
L3 0 S L1 AND L2  
L4 0 S (CEREBUS PROTEIN) AND ALBUMIN  
L5 0 S L2 AND FUSION

FILE 'BIOSIS' ENTERED AT 13:59:37 ON 06 FEB 2004

L6 0 S L2

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, JAPIO, FSTA,  
JICST-EPLUS' ENTERED AT 14:00:26 ON 06 FEB 2004

L7 1 S L2  
L8 8080 S TIMP-1 OR TISSUE INHIBITOR METALLOPROTEINASE-1  
L9 5 S L8 AND L1  
L10 378 S L8 AND FUSION  
L11 221 S L10 AND ALBUMIN  
L12 5 S L11 AND ALBUMIN FRAGMENT  
L13 9 S L11 AND SHELF-LIFE

=> s l11 and N-terminus fusion

L14 0 L11 AND N-TERMINUS FUSION

=> s l11 and C-terminus fusion

L15 0 L11 AND C-TERMINUS FUSION

=> d l11 ti abs ibib 1-25

L11 ANSWER 1 OF 221 USPATFULL on STN

TI Biospecific contrast agents

AB Methods and apparatuses for detecting a condition of a sample (including  
cervical cancers and pre-cancers) through reflectance and/or  
fluorescence imaging. A sample is obtained. One or more metallic  
nanoparticles and/or one or more quantum dots are obtained. The one or  
more metallic nanoparticles and/or one or more quantum dots are coupled  
to one or more biomarkers of the sample that are associated with the  
condition. A reflectance and/or fluorescence image of the sample is then  
taken. The image(s) exhibit characteristic optical scattering from the  
one or more metallic nanoparticles and/or characteristic fluorescence  
excitation from the one or more quantum dots to signal the presence of  
the one or more biomarkers. In this way, the condition can be readily  
screened or diagnosed.

ACCESSION NUMBER: 2004:31276 USPATFULL  
TITLE: Biospecific contrast agents

INVENTOR(S) : Sokolov, Konstantin, Austin, TX, UNITED STATES  
Korgel, Brian A., Round Rock, TX, UNITED STATES  
Ellington, Andrew D., Austin, TX, UNITED STATES  
Richards-Kortum, Rebecca, Austin, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023415	A1	20040205
APPLICATION INFO.:	US 2003-382136	A1	20030305 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361924P	20020305 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michael C. Barrett, Esq., FULBRIGHT & JAWORSKI, L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX, 78701	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	3948	

L11 ANSWER 2 OF 221 USPATFULL on STN

TI Biochips for characterizing biological processes  
AB This invention includes biochips for analysis of a variety of molecules, cell components and cells. Embodiments of this invention include devices and methods for the parallel and/or nearly parallel processing of biological analytes. Biochips can comprise a substrate, Raman signal-enhancing structures, and receptors selective and/or specific for the analyte(s) to be assayed. Biochips can be read using a Raman reader and can provide for rapid, sensitive, direct assays for physiological and/or pathophysiological conditions of interest.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31155 USPATFULL  
TITLE: Biochips for characterizing biological processes  
INVENTOR(S): Kreimer, David I., Berkeley, CA, UNITED STATES  
Nufert, Thomas H., Walnut Creek, CA, UNITED STATES  
Ginzburg, Lev, Fremont, CA, UNITED STATES  
Yevin, Oleg A., Oakland, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023293	A1	20040205
APPLICATION INFO.:	US 2002-294385	A1	20021114 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-925189, filed on 8 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-815909, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-670453, filed on 26 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156195P	19990927 (60)
	US 2001-336445P	20011114 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sheldon R. Meyer, FLIESLER DUBB MEYER & LOVEJOY LLP, Fourth Floor, Four Embarcadero Center, San Francisco, CA, 94111-4156	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	37 Drawing Page(s)	
LINE COUNT:	3572	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 221 USPATFULL on STN

TI Proteases

AB The invention provides human proteases (PRTS) and polynucleotides which identify and encode PRTS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PRTS.

ACCESSION NUMBER: 2004:31105 USPATFULL

TITLE: Proteases

INVENTOR(S): Henry, Yue, Sunnyvale, CA, UNITED STATES  
Elliott, Vicki S, San Jose, CA, UNITED STATES  
R Gandhi, Ameena, San Francisco, CA, UNITED STATES  
Lal, Preeti G, Santa Clara, CA, UNITED STATES  
Au-Young, Janice, Brisbane, CA, UNITED STATES  
Tribouley, Catherine M, San Francisco, CA, UNITED STATES  
Delegeane, Angelo M, Milpitas, CA, UNITED STATES  
Baughn, Mariah R, San Leandro, CA, UNITED STATES  
Nguyen, Danniel B, San Jose, CA, UNITED STATES  
Lee, Ernestine A, Albany, CA, UNITED STATES  
Hafalia, April J A, Daly City, CA, UNITED STATES  
Khan, Farrah A, Des Plaines, IL, UNITED STATES  
Chawla, Narinder K, Union City, CA, UNITED STATES  
Yao, Monique G, Carmel, IN, UNITED STATES  
Lu, Dyung Aina M, San Jose, CA, UNITED STATES  
Arvizu, Chandra S, San Jose, CA, UNITED STATES  
Tang, Y Tom, San Jose, CA, UNITED STATES  
Walsh, Roderick T, Canterbury, UNITED KINGDOM  
Azimzai, Yalda, Oakland, CA, UNITED STATES  
Lu, Yan, Palo Alto, CA, UNITED STATES  
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES  
Xu, Yuming, Mountain View, CA, UNITED STATES  
Reddy, Roopa, Sunnyvale, CA, UNITED STATES  
Das, Debopriya, Mountain View, CA, UNITED STATES  
Kearney, Liam, San Francisco, CA, UNITED STATES  
Kallick, Deborah A, Galveston, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023243	A1	20040205
APPLICATION INFO.:	US 2003-311035	A1	20030519 (10)
	WO 2001-US19178		20010613
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304		
NUMBER OF CLAIMS:	116		
EXEMPLARY CLAIM:	1		
LINE COUNT:	8891		

L11 ANSWER 4 OF 221 USPATFULL on STN

TI Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease

AB This invention relates to genes identified from human chromosome 20p13-p12, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate

the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31077 USPATFULL  
TITLE: Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease  
INVENTOR(S): Keith, Tim, Bedford, MA, UNITED STATES  
Little, Randall D., Newtonville, MA, UNITED STATES  
Eerdewegh, Paul Van, Weston, MA, UNITED STATES  
Dupuis, Josee, Newton, MA, UNITED STATES  
Del Mastro, Richard G., Norfolk, MA, UNITED STATES  
Simon, Jason, Westfield, NJ, UNITED STATES  
Allen, Kristina, Hopkinton, MA, UNITED STATES  
Pandit, Sunil, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023215	A1	20040205
APPLICATION INFO.:	US 2002-126022	A1	20020419 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-834597, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-548797, filed on 13 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-129391P	19990413 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053	
NUMBER OF CLAIMS:	73	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	157 Drawing Page(s)	
LINE COUNT:	20001	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:25127 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018969	A1	20040129

APPLICATION INFO.: US 2001-764875 A1 20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)
	US 2000-246532P	20001108 (60)
	US 2000-249216P	20001117 (60)
	US 2000-249210P	20001117 (60)
	US 2000-226681P	20000822 (60)
	US 2000-225759P	20000814 (60)
	US 2000-225213P	20000814 (60)
	US 2000-227182P	20000822 (60)

US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)



US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 38235

L11 ANSWER 6 OF 221 USPATFULL on STN

TI Molecules for diagnostics and therapeutics  
 AB The present invention provides purified human polynucleotides for  
 diagnostics and therapeutics (dithp). Also encompassed are the  
 polypeptides (DITHP) encoded by dithp. The invention also provides for  
 the use of dithp, or complements, oligonucleotides, or fragments thereof  
 in diagnostic assays. The invention further provides for vectors and  
 host cells containing dithp for the expression of DITHP. The invention  
 additionally provides for the use of isolated and purified DITHP to  
 induce antibodies and to screen libraries of compounds and the use of  
 anti-DITHP antibodies in diagnostic assays. Also provided are  
 microarrays containing dithp and methods of use.

ACCESSION NUMBER: 2004:18785 USPATFULL  
 TITLE: Molecules for diagnostics and therapeutics  
 INVENTOR(S): Hodgson, David M., Ann Arbor, MI, UNITED STATES  
 Lincoln, Stephen E., Potomac, MD, UNITED STATES  
 Russo, Frank D., Sunnyvale, CA, UNITED STATES  
 Albany, Peter A., Berkeley, CA, UNITED STATES  
 Banville, Steve C., Sunnyvale, CA, UNITED STATES  
 Bratcher, Shawn R., Mountain View, CA, UNITED STATES  
 Dufour, Gerard E., Castro Valley, CA, UNITED STATES  
 Cohen, Howard J., Palo Alto, CA, UNITED STATES  
 Rosen, Bruce H., Menlo Park, CA, UNITED STATES  
 Chalup, Michael S., Livingston, TX, UNITED STATES  
 Jackson, Jennifer L., Santa Cruz, CA, UNITED STATES  
 Jones, Anissa L., San Jose, CA, UNITED STATES  
 Yu, Jimmy Y., Fremont, CA, UNITED STATES  
 Greenawalt, Lila B., San Jose, CA, UNITED STATES  
 Panzer, Scott R., Sunnyvale, CA, UNITED STATES  
 Roseberry Lincoln, Ann M., Potomac, MD, UNITED STATES  
 Wright, Rachel J., Merivale, NEW ZEALAND  
 Daniels, Susan E., Mountain View, CA, UNITED STATES  
 PATENT ASSIGNEE(S): Incyte Corporation, Palo Alto, CA, UNITED STATES (U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014087	A1	20040122
APPLICATION INFO.:	US 2003-378029	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-980285, filed on 30 Nov 2001, PENDING A 371 of International Ser. No. WO 2000-US15404, filed on 31 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147500P	19990805 (60)
	US 1999-147542P	19990805 (60)
	US 1999-147541P	19990805 (60)
	US 1999-147824P	19990805 (60)
	US 1999-147547P	19990805 (60)
	US 1999-147530P	19990805 (60)
	US 1999-147536P	19990805 (60)
	US 1999-147520P	19990805 (60)
	US 1999-147527P	19990805 (60)
	US 1999-147549P	19990805 (60)
	US 1999-147377P	19990804 (60)
	US 1999-147436P	19990804 (60)
	US 1999-137411P	19990603 (60)
	US 1999-137396P	19990603 (60)
	US 1999-137417P	19990603 (60)
	US 1999-137337P	19990603 (60)
	US 1999-137173P	19990602 (60)
	US 1999-137114P	19990602 (60)
	US 1999-137259P	19990602 (60)
	US 1999-137113P	19990602 (60)
	US 1999-137260P	19990602 (60)
	US 1999-137258P	19990602 (60)
	US 1999-137109P	19990602 (60)
	US 1999-137161P	19990601 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	14819	

L11 ANSWER 7 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)
	US 2000-246532P	20001108 (60)
	US 2000-249216P	20001117 (60)
	US 2000-249210P	20001117 (60)
	US 2000-226681P	20000822 (60)
	US 2000-225759P	20000814 (60)
	US 2000-225213P	20000814 (60)
	US 2000-227182P	20000822 (60)
	US 2000-225214P	20000814 (60)

US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)

US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 26776

L11 ANSWER 8 OF 221 USPATFULL on STN

TI **Albumin fusion** proteins  
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 221 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins  
AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens",

and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13598 USPATFULL  
 TITLE: 7 Human ovarian and ovarian cancer associated proteins  
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16023		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 221 USPATFULL on STN

TI Use of bioactive glass compositions to stimulate osteoblast production  
 AB Compositions comprising bioactive glass compositions or extracts thereof which include ions in an appropriate concentration and ratio that they enhance osteoblast production, and methods of preparation and use thereof, are disclosed. The compositions can be included in implantable devices that are capable of inducing tissue formation in autogeneic, allogeneic and xenogeneic implants, for example as coatings and/or matrix materials. Examples of such devices include prosthetic implants, sutures, stents, screws, plates, tubes, and the like. Aqueous extracts of the bioactive glass compositions, which extracts are capable of stimulating osteoblast production, are also disclosed. The compositions can be used, for example, to induce local tissue formation from a progenitor cell in a mammal, for accelerating allograft repair in a mammal, for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site, and for treating tissue degenerative conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13078 USPATFULL  
 TITLE: Use of bioactive glass compositions to stimulate osteoblast production  
 INVENTOR(S): Hench, Larry L, London, UNITED KINGDOM  
 Polak, Julia M, London, UNITED KINGDOM  
 Buttery, Lee D.k., London, UNITED KINGDOM  
 Xynos, Ioannis D, Nafplion, GREECE  
 Maroothernaden, Jason, London, UNITED KINGDOM

NUMBER	KIND	DATE
-----		

PATENT INFORMATION: US 2004009598 A1 20040115  
 APPLICATION INFO.: US 2003-332731 A1 20030707 (10)  
 WO 2001-US21801 20010711  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX  
 1404, ALEXANDRIA, VA, 22313-1404  
 NUMBER OF CLAIMS: 34  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1301  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L11 ANSWER 12 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of

the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:12968 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES  
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)



US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)

US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 32038  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 221 USPATFULL on STN

TI Methods for the treatment of carcinoma

AB The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells, such as renal cell carcinoma. Such gene amplification is expected to be associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, such as renal cell carcinoma, and may act as predictors

of the prognosis of tumor treatment. The present invention is directed to novel methods of diagnosing and treating tumor, such as renal cell carcinoma or Wilms tumor.

ACCESSION NUMBER: 2004:12653 USPATFULL  
TITLE: Methods for the treatment of carcinoma  
INVENTOR(S): Gerritsen, Mary E., San Mateo, CA, UNITED STATES  
Peale, Franklin V., JR., San Carlos, CA, UNITED STATES  
Wu, Thomas D., San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009171	A1	20040115
APPLICATION INFO.:	US 2003-372683	A1	20030221 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-271690, filed on 16 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-344534P	20011018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6662	

L11 ANSWER 14 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
Rosen, Craig A., Laytonville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed		

on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L11 ANSWER 15 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7343 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)

US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)

US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

24

EXEMPLARY CLAIM:

1

LINE COUNT:

27694

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7341 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)

US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)



US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 28742  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 221 USPATFULL on STN  
TI Functional MRI agents for cancer imaging  
AB The invention relates to novel magnetic resonance imaging contrast  
agents for imaging cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:4285 USPATFULL  
TITLE: Functional MRI agents for cancer imaging  
INVENTOR(S): Meade, Thomas J., Altadena, CA, United States  
Fraser, Scott, La Canada, CA, United States  
Jacobs, Russell, Arcadia, CA, United States  
PATENT ASSIGNEE(S): Research Corporation Technologies, Inc., Tucson, AZ,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673333	B1	20040106
APPLICATION INFO.:	US 2000-715859		20001117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201816P	20000504 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Hartley, Michael G.	
LEGAL REPRESENTATIVE:	Dorsey & Whitney LLP, Silva, Robin M., Kossiak, Renee M.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2422	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 221 USPATFULL on STN

TI 50 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL  
TITLE: 50 human secreted proteins  
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2001-262066P 20010118 (60)  
 US 1997-57626P 19970905 (60)  
 US 1997-57663P 19970905 (60)  
 US 1997-57669P 19970905 (60)  
 US 1997-58666P 19970912 (60)  
 US 1997-58667P 19970912 (60)  
 US 1997-58973P 19970912 (60)  
 US 1997-58974P 19970912 (60)  
 US 1998-90112P 19980622 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 23  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 2 Drawing Page(s)  
 LINE COUNT: 33379  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 221 USPATFULL on STN  
 TI Novel human gene relating to respiratory diseases, obesity, and  
 inflammatory bowel disease  
 AB This invention relates to genes identified from human chromosome  
 20p13-p12, which are associated with various diseases, including asthma.  
 The invention also relates to the nucleotide sequences of these genes,  
 isolated nucleic acids comprising these nucleotide sequences, and  
 isolated polypeptides or peptides encoded thereby. The invention further  
 relates to vectors and host cells comprising the disclosed nucleotide  
 sequences, or fragments thereof, as well as antibodies that bind to the  
 encoded polypeptides or peptides. Also related are ligands that modulate  
 the activity of the disclosed genes or gene products. In addition, the  
 invention relates to methods and compositions employing the disclosed  
 nucleic acids, polypeptides or peptides, antibodies, and/or ligands for  
 use in diagnostics and therapeutics for asthma and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2447 USPATFULL  
 TITLE: Novel human gene relating to respiratory diseases,  
 obesity, and inflammatory bowel disease  
 INVENTOR(S): Keith, Tim, Bedford, MA, UNITED STATES  
 Little, Randall D., Newtonville, MA, UNITED STATES  
 Eerdewegh, Paul Van, Weston, MA, UNITED STATES  
 Dupuis, Josee, Newton, MA, UNITED STATES  
 Del Mastro, Richard G., Norfolk, MA, UNITED STATES  
 Simon, Jason, Westfield, NJ, UNITED STATES  
 Allen, Kristin, Hopkinton, MA, UNITED STATES  
 Pandit, Sunil, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002470	A1	20040101
APPLICATION INFO.:	US 2002-277216	A1	20021017 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-126022, filed on 19 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-834597, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-548797, filed on 13 Apr 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN & FINNEGAN, L.L.P., 345 PARK AVENUE, NEW YORK, NY, 10154		
NUMBER OF CLAIMS:	45		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 162 Drawing Page(s)  
LINE COUNT: 15810  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 221 USPATFULL on STN

TI Detection and modulation of Slit and roundabout (Robo) mediated angiogenesis and uses thereof

AB This invention is generally in the field of methods for diagnosis, treatment and prevention of various disorders involving the Slit2 mediated angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:335332 USPATFULL  
TITLE: Detection and modulation of Slit and roundabout (Robo) mediated angiogenesis and uses thereof  
INVENTOR(S): Geng, Jian-Guo, Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236210	A1	20031225
APPLICATION INFO.:	US 2003-386386	A1	20030310 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362485P	20020308 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Peng Chen, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1337	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)

US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)

US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 22457  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 221 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies  
AB The present invention relates to novel proteins. More specifically,  
isolated nucleic acid molecules are provided encoding novel  
polypeptides. Novel polypeptides and antibodies that bind to these  
polypeptides are provided. Also provided are vectors, host cells, and  
recombinant and synthetic methods for producing human polynucleotides  
and/or polypeptides, and antibodies. The invention further relates to  
diagnostic and therapeutic methods useful for diagnosing, treating,  
preventing and/or prognosing disorders related to these novel  
polypeptides. The invention further relates to screening methods for  
identifying agonists and antagonists of polynucleotides and polypeptides  
of the invention. The present invention further relates to methods  
and/or compositions for inhibiting or enhancing the production and  
function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:334953 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Birse, Charles E., North Potomac, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED  
STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING		

NUMBER	DATE
--------	------

PRIORITY INFORMATION:

US 2000-205515P	20000519 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-216880P	20000707 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-236367P	20000929 (60)
US 2000-239937P	20001013 (60)
US 2000-249210P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-231243P	20000908 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249265P	20001117 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)



US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)

US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)

US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)

US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 20415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 221 USPATFULL on STN

TI Compositions and methods for systemic inhibition of cartilage degradation

AB Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation

inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334713 USPATFULL  
TITLE: Compositions and methods for systemic inhibition of cartilage degradation  
INVENTOR(S): Demopulos, Gregory A., Mercer Island, WA, UNITED STATES  
Palmer, Pamela Pierce, San Francisco, CA, UNITED STATES  
Herz, Jeffrey M., Mill Creek, WA, UNITED STATES  
PATENT ASSIGNEE(S): Omeros Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235589	A1	20031225
APPLICATION INFO.:	US 2003-356649	A1	20030131 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-31546, filed on 18 Jan 2002, PENDING A 371 of International Ser. No. WO 2000-US19864, filed on 21 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2001-839633, filed on 20 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US24625, filed on 20 Oct 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353552P	20020201 (60)
	US 1999-144904P	19990721 (60)
	US 1998-107256P	19981105 (60)
	US 1998-105026P	19981020 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OMEROS MEDICAL SYSTEMS, INC., 1420 FIFTH AVENUE, SUITE 2675, SEATTLE, WA, 98101	
NUMBER OF CLAIMS:	155	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	6575	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 221 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel endocrine related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "endocrine antigens," and the use of such endocrine antigens for detecting disorders of the endocrine system, particularly the presence of cancers of the endocrine system and endocrine cancer metastases. More specifically, isolated endocrine associated nucleic acid molecules are provided encoding novel endocrine associated polypeptides. Novel endocrine polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human endocrine associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the endocrine system, including cancers of the endocrine system, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the

production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330759 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232975	A1	20031218
APPLICATION INFO.:	US 2002-74024	A1	20020214 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764895, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)

US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)

US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 21828  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 221 USPATFULL on STN

TI Proteases  
AB The invention provides human proteases (PRTS) and polynucleotides which identify and encode PRTS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PRTS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330138 USPATFULL  
TITLE: Proteases  
INVENTOR(S): Delegeane, Angelo M., Milpitas, CA, UNITED STATES  
Gandhi, Ameena R., San Francisco, CA, UNITED STATES  
Hafalia, April J. A., Santa Clara, CA, UNITED STATES  
Lu, Dyung Aina M., San Jose, CA, UNITED STATES  
Arvizu, Chandra S., San Jose, CA, UNITED STATES  
Tribouley, Catherine M., San Francisco, CA, UNITED STATES  
Das, Debopriya, Mountain View, CA, UNITED STATES  
Kallick, Deborah A., Portola Valley, CA, UNITED STATES  
Nguyen, Danniell B., San Jose, CA, UNITED STATES  
Lee, Ernestine A., Castro Valley, CA, UNITED STATES  
Khan, Farrah A., Glen View, IL, UNITED STATES  
Yue, Henry, Sunnyvale, CA, UNITED STATES  
Au-Young, Janice, Brisbane, CA, UNITED STATES  
Griffin, Jennifer A., Fremont, CA, UNITED STATES  
Policky, Jennifer L., San Jose, CA, UNITED STATES



Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES  
 Yang, Junming, San Jose, CA, UNITED STATES  
 Thangavelu, Kavitha, Mountain View, CA, UNITED STATES  
 Ding, Li, Creve Coeur, MO, UNITED STATES  
 Kearney, Liam, San Francisco, CA, UNITED STATES  
 Baughn, Mariah R., San Leandro, CA, UNITED STATES  
 Borowsky, Mark L., Redwood City, CA, UNITED STATES  
 Sanjanwala, Madhusudan, Los Altos, CA, UNITED STATES  
 Yao, Monique G., Carmel, IN, UNITED STATES  
 Burford, Neil, Durham, CT, UNITED STATES  
 Chawla, Narinder K., Union City, CA, UNITED STATES  
 Lal, Preeti G., Santa Clara, CA, UNITED STATES  
 Lee, Sally, San Jose, CA, UNITED STATES  
 Todd, Stephen, San Francisco, CA, UNITED STATES  
 Lo, Terence P., Foster City, CA, UNITED STATES  
 Tang, Y. Tom, San Jose, CA, UNITED STATES  
 Elliott, Vicki S., San Jose, CA, UNITED STATES  
 Azimzai, Yalda, Oakland, CA, UNITED STATES  
 Lu, Yan, Palo Alto, CA, UNITED STATES  
 Incyte Genomics, Inc., Palo Alto, CA (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232349	A1	20031218
APPLICATION INFO.:	US 2002-274639	A1	20021018 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-US22397, filed on 17 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220063P	20000721 (60)
	US 2000-221680P	20000728 (60)
	US 2000-223544P	20000804 (60)
	US 2000-224717P	20000811 (60)
	US 2000-225988P	20000816 (60)
	US 2000-227568P	20000823 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8959	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		